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Abstract 
Multimodal analgesia is recommended after surgery to reduce the consumption 
of  opioids.  The  efficacy  of  nonsteroidal  anti-inflammatory  drugs  (NSAID)  has  
been demonstrated, but they have certain adverse effects on haemostasis of 
gastric mucosa and platelet function. These adverse effects could be avoided by 
replacing NSAIDs with cyclo-oxygenase (COX)-2 inhibitors. In any case, the 
renal adverse effects of COX-2 inhibitors are thought to be equal to those of 
NSAIDs, but this is only poorly documented.  
High prevalence of persistent pain has been documented after various operations. 
Numbers from orthopaedic surgery have varied between ten and 60%. Pain is 
mostly the main indication for knee replacement surgery. The evaluation of the 
prevalence of persistent pain among these patients is important, even as an 
outcome of the surgery itself. Underlying risk factors should be known to be 
affected.  
The aim of this thesis was to study the efficacy and safety of coxibs in 
perioperative use and the prevalence and risk factors of persistent pain after total 
knee replacement. The efficacy studies (I-II) were prospective, randomized, 
double-blinded and placebo controlled. All the patients were undergoing 
laparoscopic cholecystectomy. Parecoxib 40mg or 80mg was given 
intravenously at the end of the procedure (I). Etoricoxib 120mg was given alone 
or in combination with paracetamol 1000mg as a part of premedication (II). The 
primary endpoint was to compare opioid consumption between the groups. The 
total number of patients was 148. Renal adverse effects of parecoxib were 
studied in patients undergoing laparoscopic surgery as a physiological stressful 
model with sensitive markers (III). The patients (15) enrolled were undergoing 
laparoscopic hysterectomy and received parecoxib 80mg intravenously at the 
beginning of anaesthesia. This prospective study was also double-blinded and 
placebo controlled.  
Persistent pain after total knee replacement was studied by a questionnaire 
sent to all patients operated on the period from September 2002 to February 
2004. Multivariate logistic regression analysis was performed to test assumed 
risk factors. The type of operation (primary, bilateral or revision) was assumed to 
influence the prevalence of persistent pain.The total number of patients recruited 
was 855. 
Opioid sparing effect was evident with etoricoxib, but adding paracetamol to 
etoricoxib or giving parecoxib at the end of surgery did not show any opioid 
sparing effect. In any case, the worst pain score on the ward was significantly 
lower in the parecoxib 80mg treated group than in the placebo group. Parecoxib 
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80mg  was  also  well  tolerated  in  Study  III.  The  sensitive  markers  of  both  
glomerular and tubular damage did not differ significantly between the groups.  
The  response  rate  of  the  questionnaire  was  65.7%.  Prevalence  of  persistent  
pain after knee replacement surgery was 21.5% at rest and 29.8% during 
exercise. The risk factors for persistent pain were female gender, adjusted age, 
duration of pain (more than twelve months) prior to surgery and intensity of pain 
(more than mild) during the first postoperative week. The type of surgery did not 
influence the prevalence of persistent pain. 
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Tiivistelmä 
Leikkauksen jälkeiseen kivunhoitoon suositellaan ns. multimodaalisuuden 
periaatetta. Perinteiset tulehduskipulääkkeet ovat tehokkaita vähentämään 
opioidien tarvetta, mutta niillä on omat haittavaikutuksensa kuten mahaärsytys ja 
vuotovaaran lisääntyminen. COX-2 selektiivisiltä tulehduskipulääkkeiltä nämä 
haittavaikutukset puuttuvat. Sen sijaan perinteisten ja COX-2 selektiivisten 
tulehduskipulääkkeiden oletetaan olevan samankaltaisia munuaisvaikutuksiltaan 
vaikkakin tutkimusnäyttö asiasta on vähäistä. Leikkauksen jälkeisen kivun 
pitkittyminen on yleistä. Sen esiintyvyys on ortopedisten leikkausten jälkeen 
vaihdellut kymmenestä kuuteenkymmeneen prosenttiin. Kipu on tärkein polven 
tekonivelleikkauksen syy ja yhtälailla leikkauksen tärkein tavoite on kivun 
lievittyminen. Pitkittyneen kivun yleisyyden ja mahdollisten riskitekijöiden 
selvittäminen auttavat hoidon suunnittelussa. 
Väitöstutkimuksen tarkoituksena oli selvittää ensinnäkin COX-2 
selektiivisten tulehduskipulääkkeiden tehoa ja turvallisuutta leikkauksen 
jälkeisen kivun hoidossa ja toisaalta pitkittyneen kivun esiintymistä ja 
riskitekijöitä polven tekonivelkirurgiassa. COX-2 selektiivisten 
tulehduskipulääkkeiden tehoa tutkittiin kahdessa prospektiivisessa, 
satunnaistetussa, kaksoissokkoutetussa ja lumelääke kontrolloidussa työssä. 
Leikkaustyyppinä oli molemmissa osatöissä sappirakonpoisto tähystämällä. 
Ensimmäisessä osatyössä potilaat saivat joko 40mg tai 80mg parakoksibia 
suonen sisäisesti leikkauksen lopussa ja toisessa osatyössä annettiin 
tutkimuslääke, etorikoksibi 120mg esilääkkeen yhteydessä joko yksin tai yhdessä 
parasetamoli 1g kanssa. Tärkein päätetapahtuma oli potilaiden itsensä 
annostelema opioidin määrä. Potilasmäärä ko. tutkimuksissa oli 148. COX-2 
selektiivisten tulehduskipulääkkeiden munuaisturvallisuutta tutkittiin antamalla 
parekoksibi 80mg suonen sisäisesti ja mittaamalla herkkiä munuaismarkkereita 
potilailta, joille tehtiin tähystämällä kohdunpoisto. Osatyö oli satunnaistettu, 
kaksoisokkoutettu ja lumelääke kontrolloitu. Potilaita otettiin tutkimukseen 
yhteensä 30. Pitkittyneen kivun esiintyvyyttä selvitettiin lähettämällä kaikille 
tietyllä aikavälillä polvitekonivelleikatuille potilaille postitse kysely. 
Tutkimukseen osallistui 855 potilasta. Pitkittyneen kivun riskitekijät testattiin 
monimuuttujaisella riskianalyysillä. Leikkaustyypin oletettiin vaikuttavan 
pitkittyneen kivun esiintymiseen. 
Etorikoksibi 120mg vähensi merkitsevästi leikkauksen jälkeistä 
opioidikulutusta. Sen sijaan parasetamolin lisääminen etorikoksibiin ei tuonut 
lisätehoa kivun lievitykseen. Myöskään parekoksibin tutkitut annokset eivät 
vähentäneet leikkauksen jälkeistä opioidikulutusta, vaikkakin parekoksibi 80mg 
vähensi merkitsevästi vuodeosastolla koettua pahinta mahdollista kipua. 
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Kolmannessa osatyössä vastaava annos parekoksibia ei aiheuttanut merkitseviä 
munuaismarkkereiden nousuja muutoin suhteellisen terveillä (ASAI-II, alla 60-
vuotias) potilailla eli oli hyvin siedetty munuaisten osalta  
Polvitekonivelpotilailla toteutetussa kyselytutkimuksessa oli vastausprosentti 
65,7. Pitkittynyt kipu oli yleistä: 21.5% tutkituista kärsi kivusta levossa ja 29.8% 
rasituksessa. Riskitekijöitä kivun pitkittymiselle olivat naissukupuoli, mukautettu 
ikä, leikkausta edeltävän kivuliaisuuden kesto (yli 12 kuukautta) ja leikkauksen 
jälkeisen (ensimmäisen viikon) kivun voimakkuus (enemmän kuin lievä). 
Leikkaustyypillä ei ollut vaikutusta pitkittyneen kivun esiintymiseen. 
Riskitekijöihin vaikuttamalla pystytään myös pitkittyneen kivun esiintyvyyttä 
vähentämään. Näin ollen tekonivelleikkaus tulisi pyrkiä tekemään riittävän 
ajoissa ja toisaalta leikkauksen jälkeinen kipu tulee hoitaa tehokkaasti. 
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Introduction 
Although pain is predictable after surgery, all efforts should be made firstly to 
minimize acute pain and secondly to prevent persistent pain. The most common 
concern among patients is experiencing the pain after surgery (Apfelbaum et al. 
2003)  
 Opioids are most commonly used for postoperative pain relief although their 
adverse effects, especially nausea, are well documented. Combination of 
NSAIDs or COX-2 inhibitors with opioids as a multimodal analgesia is valuable 
because they reduce the use of opioids by about 20-50 percent (Gilron et al. 
2003; Brune and Hinz 2004; Rømsing and Møiniche 2004). The COX-2 
inhibitors have lost popularity because of documented risk of adverse 
cardiovascular events in long term use (Solomon et al. 2002; Solomon et al. 
2004). However their perioperative use can be safe, especially when coxibs, 
unlike conventional NSAIDs, do not enhance surgical bleeding (Hegi et al. 2004) 
and peptic irritation can be reduced by a half compared to NSAIDs (Silverstein 
et al. 2000).  
The renal adverse effects of COX-2 inhibitors are supposed to be equal to 
those of NSAIDs, because COX-2 is also expressed in the kidneys (Breyer and 
Harris 2001; Gambaro and Perazella 2003; Gilron et al. 2003; Brune and Hinz 
2004; Rømsing and Møiniche 2004; Harris 2006; Winkelmayer et al. 2008). 
However, there are only few studies investigating (Koppert et al. 2006) or even 
reporting renal effect of coxibs in perioperative use (Malan et al. 2003; Ott et al. 
2003; Reynolds et al. 2003). 
The prevalence of persistent pain varies across operations and studies. 
(Wallace et al. 1996; Middelfart et al. 1998; Perttunen et al. 1999; Eisenberg et 
al. 2001; Kalso et al. 2001; Nikolajsen and Jensen 2001; Poobalan et al. 2003; 
Nikolajsen et al. 2004; Aasvang and Kehlet 2005; Lahtinen et al. 2006; 
Kalliomäki et al. 2008; King et al. 2008) In spite of variation, persistent 
postsurgical pain is common and has a significant effect on quality of life. This, 
in turn, means that persistent pain also has great economic significance. 
Persistent pain after joint replacement surgery is of special interest, because 
pain is mostly the main indication for surgery and also the main outcome 
variable. The prevalence of persistent pain has been the subject of some studies 
(Johnsson and Thorngren 1989; Burkart et al. 1993; Brander et al. 2003; Garcia 
et al. 2003;Harden et al. 2003; Nikolajsen et al. 2006; Elson and Brenkel 2007; 
Martinez et al. 2007; Lundblad et al. 2008) but the risk factors for persistent pain 
have been evaluated more rarely (Johnsson and Thorngren 1989; Brander et al. 
2003; Harden et al. 2003; Nikolajsen et al. 2006; Lundblad et al. 2008). 
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Our first two studies joined the clinical studies evaluating the efficacy of 
treatment methods in acute postsurgical pain. The third study was intended to 
investigate renal adverse effects of COX-2 inhibitor, parecoxib. The fourth study 
revealed  the  prevalence  and  the  risk  factors  of  persistent  pain  in  patients  after  
total knee replacement.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
Review of the literature 
Pain is defined by the International Association for the Study of Pain (IASP) as 
an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage (Merskey and 
Bogduk 1994). Although pain is a psychological sensory experience, the 
biomedical model of pain is well documented. 
1. Mechanisms of postsurgical pain 
The cascade from tissue damage to the sensation of pain can be divided into four 
steps: transduction, transmission, modulation and perception (Kalso et al. 2009). 
Transduction refers to the action potential of nociceptors, which is caused by 
tissue damage. Transmission, in turn, refers to the signal transporting system 
from periphery to brain and modulation refers to all the inhibitory and excitatory 
events along that pathway. Perception is the end stage cascade, the sensation of 
pain (Kalso et al. 2009). 
In the peripheral nervous system there are four main types of sensory afferent 
fibres: A?, Aß, A? and c. A?-fibres and Aß-fibres are both large in diameter, 
myelinated and responsible in propriosepting (A?, Aß) or heavy touch (Aß). A?-
fibres are thinly myelinated and c-fibres nonmyelinated, but both can be termed 
nociceptors or pain fibres. The diameter is small, the conductance is slow and the 
response threshold to stimulus - mechanical, chemical or thermal - is high. In a 
clinical situation they can be differentiated by temperature- A?-fibres are 
responsible in cold and c-fibres in hot temperature sensation (D'Mello and 
Dickenson 2008; Kalso et al. 2009).  
These afferent pain fibres transmit impulses from the periphery through the 
dorsal  root  ganglion  to  the  dorsal  horn  of  the  spinal  cord,  where  they  synapse  
with projection neurons and interneurons. The spinal cord is divided into laminas 
according to anatomical features. C-fibres synapse with projection neurons, 
which are located in lamina I-II and V and A?-fibres synapse with neurons in 
lamina  I  and  V  (Kalso  et  al.  2009).  These  projection  neurons  are  called  
nociceptive specific cells or wide dynamic range (WDR) neurons depending on 
which afferent fibres they synapse with (D'Mello and Dickenson 2008). WDRs 
are located in lamina V and synapse with a wider variety of fibres (Aß, A?, c) 
(D'Mello and Dickenson 2008). These WDRs are able to increase the responses 
evoked after repeated stimuli (so-called wind-up) (D'Mello and Dickenson 2008; 
Kalso et al. 2009). Projection neurons from lamina I innervate areas such as the 
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parabrachial area and periaqueductal grey, which are affected by limbic areas. 
Lamina V neurons mainly project to the thalamus via the spinothalamic tract. 
From the thalamus, the primary sensory pathway projects to the various cortical 
regions (D'Mello and Dickenson 2008). Other ascending sensory tracts 
projecting pain are spinoreticular, spinomesencephalic, spinotectal and 
spinohypothalamic (Soinila et al. 2006). These all use the anterolateral column of 
the spinal cord on the contralateral side. Some spinocerebellar tracts include pain 
fibres in addition to proprioseptic ones (Soinila et al. 2006).  
 
Figure 1. Simplified pathway from tissue damage to pain sensation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thala-
mus 
Pain matrix 
in cortex 
Laminas I-V in 
dorsal horn  
Tissue 
damage 
Interneuron 
and 
projection 
neuron 
Dorsal root 
ganglion 
 Limbic 
areas 
SPINAL CORD  
BRAIN 
PERIPHERAL 
AFFERENT 
FIBRES: 
C and A?  
 
 
18 
 
The  function  of  interneurons  in  the  spinal  cord  may  be  either  excitatory  or  
inhibitory. The major excitatory neurotransmitter is glutamate and the major 
inhibitory one is GABA (D'Mello and Dickenson 2008). In addition, peptides 
like  endogenous  opioids,  substance  P  and  somatostatin  are  documented  
neurotransmitters of interneurons (Kalso et al. 2009). These interneurons, in turn, 
are controlled by descending pathways from the brainstem and the 
hypothalamus. They are all responsible for modulation. Melzack and Wall 
published this gate-control theory of pain as early as 1965 (Melzack and Wall 
1965). 
The perception of pain is a cortical process, in which various cortical regions 
take part. Imaging facilities (CT, PET, SPECT, fMRI, MEG) have been able to 
show that at least primary and secondary somatosensory cortex, insular cortex, 
anterior cingulated cortex and prefrontal cortex are involved in pain perception. 
These areas together are called the pain matrix (D'Mello and Dickenson 2008). 
Visceral pain sensation, perception is different, from somatic perception. The 
visceral organs have only few nociceptors (A? and c). In addition Aß responsive 
to pressure sensation projects pain from the visceral system. Because of these, 
visceral pain is poorly localized and different in nature-more dull or vague than 
somatic pain. Interaction with projection neurons in the dorsal horn of the spinal 
cord causes pain to be referred to different parts of the body confounding 
patients and clinicians (Kalso et al. 2009). 
1.1 Pathophysiology of acute postsurgical pain 
A surgical procedure always damages the operated and surrounding tissues. This 
damage releases chemical mediators like protons, ATP, serotonin, histamine, 
bradykinin and arachidonic acid from injured and inflammatory cells (Kalso et 
al. 2009). Arachidonic acid is converted via the cyclo-oxygenase pathway into 
prostanoids and leukotrienes. All these mediators in turn directly or indirectly 
stimulate peripheral sensory neurons and cause so-called peripheral sensitisation, 
primary hyperalgesia, by reducing the threshold of nociceptive receptors and 
increasing the excitability of the neurons (Kehlet et al. 2006a). The excessive 
stimulation of the nociceptive neurons also results in the release of stored 
neuropeptides like substance P, which is a potent activator of inflammatory 
response in surrounding tissue (Kalso et al. 2009). A vicious circle has been 
created. This is illustrated schematically in Figure 2. 
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Figure 2. Schematic presentation of transmitters in tissue injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Central sensitisation, secondary hyperalgesia, is the next step, where continuing 
stimulus from the periphery causes increased and altered excitability of the 
sensory neurons in the dorsal horn of the spinal cord (Kehlet et al. 2006a). One 
primary mechanism in the spinal cord is so-called wind-up, which is mediated by 
glutamate via NMDA receptors (D'Mello and Dickenson 2008; Kalso et al. 
2009). Central sensitisation is also mediated by the central nervous system with 
descending  pathways  to  the  dorsal  horn  of  the  spinal  cord  (D'Mello  and  
Dickenson 2008; Kalso et al. 2009).  
Fortunately, these processes are reversible and the inflammatory mediators 
gradually disappear once the wound has healed (Kehlet et al. 2006a). Primary 
hyperalgesia can be evoked by a stimulus to the injured area, but secondary 
hyperalgesia can also be provoked from the surrounding area (Kalso et al. 2009). 
1.2 Pathophysiology of persistent postsurgical pain 
The pathophysiology of persistent pain is similar to that of acute variety if the 
reason for persistent pain is a complication such as infection, incorrect fracture 
correction etc. (Kehlet et al. 2006a). The pain should then abate if the peripheral 
driving force is removed.  
Tissue injury: 
ATP, H+ 
inflammatory mediators: 
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Nociceptive neuron 
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The situation is totally different, if the reason for persistent postsurgical pain 
is  surgical  injury  to  any  part  of  the  sensory  pathway  system.  Although  the  
primary events of nerve injury are quite similar to any tissue damage, causing 
peripheral and central sensitization in time, the main difference arises from nerve 
injury itself. If an injured axon is not restored to its target, this specific neuron 
dies. Gradually, apoptosis also destroys the neurons in the dorsal horn of the 
spinal  cord  and  in  the  grey  matter  of  the  cortex.  During  the  process,  chemicals  
from dying cells aggravate the inflammation and sensitization. The consequence, 
the combination of sensory loss with paradoxical hypersensitivity, is a key 
feature of neuropathic pain (Kehlet et al. 2006a). Welch et al. reported a 
prevalence of only 0.03% in nerve injuries after surgery (Welch et al. 2009). The 
data were retrospectively collected from different databases including the bias 
that not all cases were reported to these data sources. The true prevalence of 
nerve injuries after surgery is not known, but it exceeds these numbers (Prielipp 
and Warner 2009). 
Although biomedical models of pain are useful, they are not always able to 
explain persistent pain. Persistent pain can develop without preexisting nerve 
damage (Prielipp and Warner 2009). By contrast, nerve damage does not 
necessarily cause pain. The careful technique for identifying and sparing 
intercostobrachial nerve in axillary node dissection did not reduce the incidence 
of pain although skin sensation was better preserved than in standard dissection 
(Abdullah  et  al.  1998).  The  biomedical  model  needs  to  be  expanded  to  a  
biopsychosocial model, where cultural differences, past experiences, personality 
variables, hormonal state etc. are taken into account (Gatchel et al. 2007).In 
addition, there are increasing amount of data about genetic predisposition to 
persistent pain (Belfer et al. 2004;Diatchenko et al. 2005;Stamer and Stuber 
2007a;Stamer and Stuber 2007b;George et al. 2008;Reimann et al. 2010).  
2. Pharmacological treatment of acute postsurgical pain 
The WHO has developed a recommendation, a three-step ladder, for cancer pain 
(http://www.who.int/cancer/palliative/painladder/en/). This recommendation has 
been adapted to all kinds of acute pain. The idea is to start immediate 
administration of drugs in the following order: nonopioids (NSAID, 
paracetamol), mild opioids (codeine, tramadol) and strong opioids (morphine, 
oxycodone) until the patient is free from pain. To maintain this state, drugs 
should be given regularly rather than “on demand”. Antidepressants, sedatives 
and surgical interventions are mentioned as adjuvants. The following review of 
pharmacological treatment of acute pain is written in the order of the WHO 
ladder. The adjuvants, except regional anaesthesia as anaesthesiological 
technique, have been omitted. 
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2.1 Paracetamol 
Paracetamol, also called acetaminophen, was first synthesized by Harmon 
Northrop Morse in 1877 (Morse 1878), but it was not until the early fifties that 
paracetamol came into wider clinical use. However, the mechanisms of the 
action of paracetamol are still not fully understood. It is usually mentioned to be 
a weak inhibitor of prostaglandin production although the molecular mechanism 
is uncertain.  
In 2002 Chandrasekharan et al. were able to introduce a variant of COX-1, 
which was depressed by paracetamol and called for COX-3 (Chandrasekharan et 
al. 2002). This enzyme was detectable in dog (Chandrasekharan et al. 2002) and 
rat  brain  (Kis  et  al.  2003).  This  was  believed  to  solve  the  question  of  the  
mechanism of paracetamol. Later it became evident that the enzyme could not be 
found in human brain and the action of the enzyme was not strong enough to 
explain the analgesic and antipyretic effect of paracetamol (Schwab et al. 
2003a;Schwab et al. 2003b;Graham and Scott 2005). 
Paracetamol is today believed to act more like COX-2 inhibitors. COX-2 
inhibition is chosen if the concentration of arachidonic acid is low and COX-1 
inhibition if the concentration of arachidonic acid is high (Graham and Scott 
2005).  This  is  line  with  the  fact  that  paracetamol  works  rather  in  the  central  
nervous system than on the periphery, where the concentration of arachidonic 
acid must be high because of ongoing trauma or inflammation. In addition, 
paracetamol is known to act in the spinal cord by stimulating the descending 
serotonergic pathways and thus inhibiting the nociceptic pathways from the 
periphery (Bonnefont et al. 2003; Graham and Scott 2005).  
The pharmacodynamic and pharmacokinetic profiles of paracetamol are 
summarized in Table 1.  
 
Table 1 Pharmacodynamic and pharmacokinetic profiles of paracetamol 1g 
po 
 
Peak plasma concentration 12.3µg/l 
Time to peak plasma concentration 1h 
IC50 (COX-2/COX-1)* 44/94µg/l 
Mean oral availability 80-88% 
Route of elimination hepatic 95%, renal 5% 
Elimination half-life 2.8h 
* IC50 is indicated by lipopolysaccaharide-induced prostaglandin synthesis 
(COX-2) and thromboxane B2 generation (COX-1) in human blood cells 
(Sciulli et al. 2003). 
 
The  analgesic  efficacy  of  paracetamol  in  acute  pain  is  known to  be  superior  to  
placebo, but in most studies it has been shown to be inferior to NSAIDs. The 
combination of paracetamol with NSAIDs has been believed to increase the 
efficacy of both. The evidence to support this is still rather poor (Rømsing et al. 
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2002), but the lack of adverse effect supports the combination treatment 
(Hyllested et al. 2002).  
Adverse effects of paracetamol are rare, < 1/10000 (Duggan and Scott 2009). 
The most serious one is hepatotoxicity. An overdose of paracetamol can lead to 
irreversible liver necrosis which may be lethal. The necrosis is due to the toxic 
metabolite of paracetamol. The single adult dose to cause severe liver damage is 
150-250mg/kg, which is ten times the recommended one (Prescott et al. 1971). 
However, among chronic alcoholics even therapeutic doses of paracetamol have 
been reported to be harmful (Seeff et al. 1986) although the underlying 
mechanism is not clear (Prescott 2000a; Prescott 2000b). Paracetamol is believed 
to act by COX-2 inhibition, but doubling the recommended single dose to 
2000mg seems to inhibit platelet function (Munsterhjelm et al. 2005).  
Paracetamol can be administered enterally and parenterally. Bioavailability is 
almost 100% if orally administered. The analgesic effect begins within 30 
minutes and the maximum effect is achieved in one hour if orally administered. 
The elimination half-life of paracetamol is only 2 hours, necessitating 
administration three to four times a day. The onset of analgesia occurs within 5-
10 ten minutes of the intravenous administration of paracetamol but the 
pharmacodynamic profile is otherwise similar to that of enteral administration. 
The recommended single doses are 1g for adults and 15mg/kg for children 
(Duggan and Scott 2009). These  doses  are  the  same  for  enteral  and  parenteral  
route, although the bioavailability of suppositories is known to be variable and 
only 80% of that of tablets. Therefore, the single dose of paracetamol 
suppositories needed for pain relief after surgery has to be as high as 40-60mg/kg 
(Korpela et al. 1999). The rate of absorption is also slower and maximum plasma 
concentration is achieved about 2-3 hours after rectal administration (Korpela et 
al. 1999). The recommended doses for antipyretic effect are half of that needed 
for analgesic effect (Plaisance and Mackowiak 2000), confusing patients, parents 
and partly clinicians, too. 
2.2 Nonsteroidal anti-inflammatory drugs 
Nonsteroidal anti-inflammatory drugs are known to act by inhibition of the 
cyclo-oxygenase enzyme, which catalyzes the synthesis of prostaglandins from 
arachidonic acid (Vane 1971). The COX gene was cloned in 1988 and since then 
two isoforms have been identified: COX-1 and COX-2 (Gajraj 2003). COX-1 is 
expressed more constitutively throughout the body. COX-2 is expressed 
predominantly in reaction to inflammation by the inflammatory cells. COX-1 is 
essential in homeostatic processes (gastrointestinal protection, platelet 
aggregation, renal function), but later studies have revealed that COX-2 also has 
certain role in homeostasis although its main role is pathologic processes such as 
pain, fever and carcinogenesis (McCrory and Lindahl 2002). The simplified 
cyclo-oxygenase pathway with differential expression of COX-1 and COX-2 is 
illustrated in Figure 3. Pharmacological treatment with action sites is represented 
by *.  
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Figure 3. Cyclo-oxygenase pathway  
 
 
 
 
The efficacy of NSAIDs in acute pain has been demonstrated in a vast number of 
studies and summarized in meta-analyses showing numbers needed to treat 
around 2-3 (http://www.thecochranelibrary.com).  The  opioid-sparing  effect  is  
approximately 35% (Rorarius et al. 1993) and they seem to work even better 
than opioids in movement-evoked pain (Pavy et al. 1995) .  
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 The principle behind the adverse events is based on the mechanism of 
NSAIDs. Inhibition of cyclo-oxygenase enzyme results in the shunting of 
arachidonic acid to the lipoxygenase pathways, resulting in increased leukotriene 
synthesis. This in turn increases the probability of broncospasm. Inhibition of 
COX-1 causes adverse effects by disrupting the gastric mucosa and platelet 
aggregation. The adverse effect in platelet aggregation is beneficial in the 
prophylaxis of thrombotic events (myocardial, cerebrovascular etc.) and the 
absence of that adverse effect may even be harmful with selective COX-2 
inhibitors, coxibs (Solomon et al. 2002; Solomon et al. 2004). Renal adverse 
effects of NSAIDs will be discussed together with COX-2 inhibitors (see text in 
Chapter 3). Fracture healing may also be disturbed by NSAIDs but on the other 
hand, they have a beneficial effect on ectopic bone formation (Beck et al. 2005; 
Vuolteenaho et al. 2008; Boursinos et al. 2009). NSAIDs have also been studied 
in  the  primary  prevention  of  cancer  and  efficacy  has  been  reported  in  a  meta-
analysis of colorectal (Rostom et al. 2007) and lung cancer (Khuder et al. 2005). 
2.3 COX-2 inhibitors 
COX-2 selective NSAIDs, so called COX-2 inhibitors or coxibs, were widely 
introduced in 1999, one hundred years after the first NSAID, acetylsalicylic acid 
(Aspirin). Celecoxib, rofecoxib, valdecoxib, parecoxib and etoricoxib were those 
introduced, although nimesulide and meloxicam were marketed in Europe long 
before the discovery of COX-2 offering precursor molecules for these newer 
COX-2 inhibitors (Gilron et al. 2003).  
The COX-2 inhibitors were reported to be equally effective in pain relief in 
acute postoperative pain model, which was underlined in several reviews 
(http://www.biomedcentral.com). Only celecoxib failed to prove its efficacy 
when compared to NSAIDs (Rømsing and Møiniche 2004). Parallel to these 
efficacy studies were studies demonstrating a positive profile in gastrointestinal 
adverse effects (Bombardier et al. 2000; Silverstein et al. 2000) because of the 
absence of COX-1 inhibition.  
Only some years after launching, the results of the so-called VIGOR trial 
were published, showing increased risk for cardiovascular events in rofecoxib 
compared to naproxen (Mukherjee et al. 2001). To confuse the audience, the 
CLASS  trial  was  unable  to  show  similar  risk  with  celecoxib  (Silverstein  et  al.  
2000). Finally, rofexocib together with valdecoxib were withdrawn from the 
market in 2004 after the so-called APPROVe trial (Bresalier et al. 2005). This 
was in line with the APC study (Solomon et  al.  2005).  In both trials,  the coxib 
treated patients with colorectal neoplasia showed an increased risk for 
cardiovascular events (Bresalier et al. 2005; Solomon et al. 2005). Later the 
MEDAL Programme failed to show any difference in thrombotic cardiovascular 
events between etoricoxib and diclofenac (Cannon et al. 2006).  
The story of the latest and most selective COX-2 inhibitor, lumiracoxib, was 
even shorter than that of rofecoxib and valdecoxib. It was introduced in 2005 and 
only two years later it was withdrawn from the market 
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(http://www.tga.gov.au/recalls/2007/lumiracoxib.htm) in most countries because 
of several serious liver adverse events.  
The only COX-2 inhibitors still available for clinical use are celecoxib, 
parecoxib and etoricoxib. Celecoxib is less selective than the others and after 
failing in acute pain models (Rømsing and Møiniche 2004), it is mostly only 
used long term. Parecoxib is a COX-2 inhibitor, which can be administered 
parenterally. It is a pro-drug metabolized by the liver to valdecoxib. The 
analgesic effect of valdecoxib starts within 10 minutes and the maximum effect 
is reached within half an hour. The elimination half-life of valdecoxib is 8 hours. 
Administered 40mg twice a day, steady-state plasma concentration is achieved in 
4 days (Cheer and Goa 2001). Etoricoxib is orally administered and its 
bioavailability is almost 100 %. The analgesic effect of etoricoxib begins within 
30 minutes and the maximum effect is achieved within one hour. The elimination 
half-life  of  etoricoxib  is  22  hours  allowing  administration  once  a  day.  Steady-
state  plasma  concentration  is  reached  with  120mg  in  7  days  (Cochrane  et  al.  
2002). After steady-state achievement both drugs are recommended to be 
administered in reduced amounts. The pharmacodynamic and pharmacokinetic 
parameters of investigational COX-2 inhibitors are summarized in Table 2.  
 
Table 2. Pharmacodynamic and pharmacokinetic profiles of parecoxib and 
etoricoxib 
 
 Parecoxib 40mg iv Etoricoxib 120mg po 
Peak plasma concentration 1.02mg/l 3.6mg/l 
Time to peak plasma 
concentration 
0.6h 1h 
IC50 (COX-2/COX-1)* 0.005/140 µg/l 1.1/ 116 µg/l 
Mean oral availability - 100% 
Route of elimination renal hepatic 
Elimination half-life                                      
(parecoxib/valdecoxib) 
0.69/7.88h 22h 
* IC50 is indicated by lipopolysaccaharide-induced prostaglandin synthesis 
(COX-2) and thromboxane B2 generation (COX-1) in human blood cells 
(Tacconelli et al. 2002). 
 
The renal adverse effects of COX-2 inhibitors will be discussed later in Chapter 
3. In addition to these renal adverse effects and cardiovascular adverse effects 
mentioned above, COX-2 inhibitors share the effects on bone formation and 
remodelling with traditional NSAIDs. In any case, the data from human studies 
are sparse (Beck et al. 2005; Vuolteenaho et al. 2008; Boursinos et al. 2009). 
Similarily, COX-2 inhibitors have been suggested to be beneficial in cancer 
prophylaxis (Rostom et al. 2007).  
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2.4 Opioid analgesics 
Acute pain, which is moderate or severe in intensity, generally cannot be solved 
without  opioids.  Opioids  act  through  specific  receptors  (µ,  ?,  ?,  ORL1) on 
injured tissue, in the dorsal horn of the spinal cord and in the brain (Kalso et.al. 
2009).  
The  efficacy  of  opioids  is  well  documented,  but  so  are  the  adverse  effects.  
Some of the adverse effects are more harmful than others, but all of them cause 
patients severe discomfort. The most potent adverse effect, mediated centrally by 
µ-opioid receptors, (Dahan et al. 2010) is respiratory depression. The incidence 
of respiratory depression is low, 0.5% (Dahan et al. 2010), but significant, 
because this adverse effect can be fatal. Fortunately, the respiratory drive of a 
patient with marked postoperative pain is increased, making opioid treatment 
safe in general. By contrast, nausea and vomiting are very common adverse 
effects and consequences from direct central stimulation of the Chemoreceptor 
Trigger Zone (Kalso et al. 2009). Opioid-related PONV may jeopardize early 
recovery after surgery. Therefore, opioid-sparing regimens are welcome in 
clinical acute pain treatment. Opioid related ileus and constipation are in turn due 
to decreased smooth muscle contractility. Pruritus is the most common adverse 
effect  of  spinal  administration  (Dahan  et  al.  2010).  In  an  animal  study,  the  
existence of a specific spinothalamic pathway for itch has been demonstrated 
(Andrew and Craig 2001). Opioids reduce the inhibition of this pathway 
allowing the spontaneous activity of central itching neurons to increase (Schmelz 
2001). Another issue recently addressed is opioid-induced hyperalgesia, which is 
documented even after short-term administration of short-acting opioids like 
remifentanil (Guignard et al. 2000). This phenomenon is also called acute opioid 
tolerance and may apply other opioids, too (Angst and Clark 2006). Both 
analgesic and adverse effects differ between genders and individuals. Females 
are more sensitive to the effects of opioids, although the onset of analgesia is 
faster in males (Dahan et al. 2008).  
Opioid analgesics can be administered in several ways. Oral, intramuscular, 
intravenous, sublingual, intranasal, intra-articular, transcutaneous and intraspinal 
administrations all have their advantages.  
2.5 Regional anaesthesia 
Regional anaesthesia, i.e. central and peripheral blocks and wound infiltration 
can be regarded as pharmacological treatment of acute pain (Bonica 1984). It is 
most  commonly  used  as  a  regimen  of  postoperative  care,  but  regional  
anaesthesia could also be utilised in palliative and trauma care. Properly 
designed and performed, regional anaesthesia has proved to be beneficial to 
patients suffering from acute pain. A recently published review on central 
neuraxial blocks showed a clear correlation between blocks and improved 
comfort but also between blocks and reduced morbidity and mortality after 
surgical procedure (Breivik et al. 2010). 
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Despite the convincing evidence on the benefits of regional anaesthesia, there 
are some disadvantages, too. Neuraxial blocks are invasive in nature and there is 
always a risk of infection and needle or catheter-induced nerve injury. Pain and 
paraesthesia have been shown to be important predictors of nerve damage 
underlying the importance of performing blocks in the awake state (Faccenda 
and Finucane 2002). Ultra-sound guided regional anaesthesia has been believed 
to increase the safety of patients but a meta-analysis of 22 RCTs failed to prove 
any increased safety regarding peripheral neural injury when compared to 
standard nerve localisation tools (Neal 2010). Fortunately, the rate of 
complications was low in both groups. Liu et al. have reported the greatest 
number of symptomatic nerve injuries after interscalene blocks at 1 week: 8% in 
an ultra-sound guided group, and 11% in a nerve stimulation group (Liu et al. 
2009). Accidental vascular puncture with increased systemic toxicity of local 
anaesthetic was more common with patients whose regional anaesthesia was 
performed with standard nerve localisation than with ultra-sound guided 
technique (Neal 2010). This systemic toxicity (central nervous system toxicity, 
cardiotoxicity) of local anaesthetic can be further reduced by reducing the 
volume of anaesthetic which goes in line with ultra-sound guided blocks. Newer 
agents, ropivacaine and levobupivacaine have enhanced the safety profile when 
compared to bupivacaine (Veering 2003). Local anaesthetic also has local 
neurotoxicity, which is most obvious with spinally used 5% lidocaine (Rigler et 
al. 1991). The contact myotoxicity of local anaesthetic is known to cause 
necrosis of the skeletal muscles. Fortunately, this necrosis is followed by rapid 
regeneration of the muscle cells (Hogan et al. 1994). 
Complications associated with central neuraxial blocks are rare but serious. 
One study covering all complications after central neuraxial blocks in Sweden 
during the 1990s, reported an incidence of 1:52000 in spinal haematomas after 
central neuraxial blocks (1:18 000 after epidural technique and 1:160000 after 
spinal technique) (Moen et al. 2004). Seventy-two percent occurred during the 
second half of the decade (Moen et al. 2004), which is in line with the increasing 
use of antihaemostatic drugs. Other risk factors for spinal bleeding are 
haemostatic disorders, anatomical abnormalities of the spine and spinal blood 
vessels, elderly patients, renal and hepatic impairments (Breivik et al. 2010). To 
minimize the risk of this serious complication, recommendations for safe clinical 
practice with neuraxial blocks have recently been published (Breivik et al. 2010). 
Several  studies  have  tried  to  confirm  that  regional  anaesthesia  could  reduce  
postsurgical persistent pain (Senturk et al. 2002; Tiippana et al. 2003; Nikolajsen 
et al. 2004), but the evidence is not convincing (Macrae 2008; Breivik et al. 
2010). 
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3. Cyclo-oxygenase inhibitors and renal function 
Although COX-2 is induced at the sites of inflammation, both COX-1 and COX-
2 are highly expressed in the kidneys. The localization of COX-1 and COX-2 is 
illustrated in Figure 4. COX-1 is expressed in the medullar collecting ducts and 
in interstitial cells. COX-2 in turn has been detected in cortical thick ascending 
limbs including macula densa and the renal vascular components, podocytes and 
arteriolar smooth muscle cells (Breyer et al. 2001). In addition, COX-2 
expression can be upregulated in conditions where the production of 
prostaglandins has become crucial, such as renal artery stenosis (Mann et al. 
2001) and heart failure (Abassi et al. 2001). 
COX-1 and COX-2 derived prostaglandins have several roles in the kidney. 
In euvolemic, unstressed state these roles are meaningless, but in 
pathophysiological states they become critical. For instance, sympathetic 
activation following several perioperative situations like volume depletion, pain 
and nausea, constricts afferent arterioles of the glomerulus reducing the 
glomerular filtration rate (GFR). Both PGI2 and  PGE2 can counteract and 
produce vasodilatation of renal arterioles maintaining GFR. PGI2 production in 
turn increases renin release, which in turn activates the renin-angiotensin-
aldosterone-system. Prostaglandins also inhibit active absorption of sodium in 
thick ascending limbs and collecting ducts (Breyer et al. 2001; Gambaro and 
Perazella 2003; Harris 2008).  
3.1 Clinical implications of COX inhibitors for renal function 
The inhibition of the synthesis of these prostaglandins by NSAIDs and COX-2 
inhibitors causes a variety of clinical renal syndromes. The cyclo-oxygenase 
inhibitors can decrease the renal blood flow in the afferent arteriole. This in turn 
decreases intraglomerular pressure and GFR will be reduced. Acute renal failure 
(ARF) will manifest. If the stressed state persists, acute renal ischaemia turns to 
acute tubular necrosis. The use of cyclo-oxygenase inhibitors also results in a 
decreased release of renin. The lowered production of renin in turn decreases 
aldosterone secretion, which can lead to hyponatremia and hyperkalemia. The 
use of both NSAIDs and COX-2 inhibitors may also result in sodium and water 
retention with oedema, hypertension and congestive heart failure formation 
(Breyer et al. 2001; Gambaro and Perazella 2003; Barkin and Buvanendran 
2004).  
The prolonged use of cyclo-oxygenase inhibitors has also led rarely to 
syndromes like analgesic nephropathy, interstitial nephritis, nephrotic syndrome, 
papillary necrosis and cancer (Gambaro and Perazella 2003; Markowitz and 
Perazella 2005).  
Acute renal failures associated with conventional NSAIDs are well 
documented (Fong and Cohen 1982; Feldman et al. 1997; Whelton 1999; 
Kallanagowdar  et  al.  2006).  The  overall  incidence  of  ARF  was  around  one  
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percent and the risk of ARF was doubled with more than five days prolonged 
therapy  with  ketorolac  (Feldman et  al.  1997)  In  addition,  sodium retention  and  
oedema are found in five percent of the population taking NSAIDs (Whelton 
2000)  
The renovascular effect of COX-2 inhibitors may be even more evident with 
them than with traditional NSAIDs (Cannon et al. 2006; Chan et al. 2009). These 
results are in line with the MEDAL Programme, where discontinuations because 
of hypertension were more frequent in the etoricoxib-treated group (incidence 
2.3 %) versus the diclofenac-treated group (incidence 0.7%) (Cannon et al. 
2006). In addition, congestive heart failure and oedema were more common 
causes of discontinuation in the etoricoxib group with incidences of 0.7 and 
1.9% respectively (Cannon et al. 2006). There are also some case reports of ARF 
associated with the use of COX-2 inhibitors in patients with predisposing factors 
(Perazella and Eras 2000; Braden et al. 2004).  
3.2 Novel biomarkers of renal function 
Novel sensitive biomarkers of renal function are cystatin C, ?-1-microglobulin 
and glutathione-s-transferases ? and ?. The sites of biomarkers in the nephron 
are presented in Figure 4. Cystatin C and ?-1-microglobulin are in clinical use 
but glutathione-s-transferases are used only in research. 
Cystatin C is the plasma protein, which is produced regularly by all nucleated 
cells. The production of cystatin C is less dependent on age, gender, diet and 
muscle  mass  than  the  production  of  creatinine.  Cystatin  C  works  as  a  cysteine  
protease inhibitor. It is freely filtrated by the glomerulus. The serum level of 
cystatin C increases if the glomerular filtration rate decreases. The upper limit of 
the normal value is 1.4mg/l for those under 50 years and 1.5mg/l for those over 
50 years (Harmoinen et al. 2003; Shlipak et al. 2006). A meta-analysis 
comparing serum cystatin C to creatinine as markers for GFR showed the 
superiority of cystatin C (Dharnidharka et al. 2002). 
?-1-microglobulin is the plasma protein which is synthesized by hepatocytes. 
It is filtrated relatively freely by the glomerulus and reabsorbed and catabolised 
by the proximal tubular cells. The urinary level of ?-1-microglobulin is used to 
measure proximal tubular dysfunction. The upper limit of normal value is 8mg/l. 
?-1-microglobulin is responsible for immunomodulation. (Akerström et al. 2000)  
Glutathione-s-transferases (GST) are cytosolic enzymes and involved in the 
detoxification of endogenous and exogenous substances. ?-GST is localized in 
the proximal and ?-GST in the distal tubular cells of the kidney. Damage to these 
cells is associated with an increase in urinary levels of specific GST (Svendsen et 
al. 2000). The normal values corrected for urinary creatinine are 0.10-1.93 
µg/mmol with ?-GST and 0.25-7.41 µg/mmol with ?-GST. 
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Figure 4. Localizations of COX-1, COX-2 and biomarkers in the nephron. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Persistent postsurgical pain 
Despite our ability to treat acute pain pharmacologically during and immediately 
after surgery, a remarkable part of that pain persists and causes a major problem 
for  patients  recovering  from  surgery.  The  definition  of  persistent  or  chronic  
postsurgical pain varies, but the most referred to definition was proposed by 
Macrae W.A. (Macrae 2008). The pain should have developed after a surgical 
procedure, other causes of pain must be excluded and the pain should be of least 
two months duration (Macrae 2008). On the other hand, most trials studying 
chronic pain assume that the minimum duration of the pain is three months 
(Merskey and Bogduk 1994) and this definition is sometimes also used in the 
postsurgical literature (Kehlet et al. 2006b). The recommendation for RCTs of 
chronic pain made by the IMMPACT consensus meeting is also in line with the 
IASP definition, but encourages the use of a minimum duration of six months to 
increase the specificity of trials (Dworkin et al. 2010).  
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4.1 Epidemiology of persistent pain in different types of surgery 
 
The prevalence of persistent pain after different types of surgery has been 
summarised in the following Table 3. The most common is persistent pain after 
amputation (Perkins and Kehlet 2000; Nikolajsen and Jensen 2001) and 
thoracotomy (Perttunen et al. 1999; Kalso et al. 2001). In both situations, as 
many as half of patients operated on suffer from persistent pain (Perttunen et al. 
1999; Kalso et al. 2001; Nikolajsen and Jensen 2001) .The intensity of the 
persistent pain has in general been from mild to moderate (Kehlet et al. 2006b). 
Only a minority (5-10%) of patients operated on have suffered from severe, 
disabling pain (Kehlet et al. 2006b).  
 
Table 3. Prevalence of persistent pain after surgical procedures 
 
Surgical procedure Prevalence of 
persistent 
pain (%) 
References 
Amputation 60-80 (Perkins and Kehlet 2000; Nikolajsen 
and Jensen 2001) 
Thoracotomy 40-60 (Perttunen et al.1999; Kalso et al. 
2001) 
Sternotomy 20-50 (Eisenberg et al. 2001; Lahtinen et al. 
2006; King et al. 2008) 
Breast surgery 10-60 (Tasmuth et al. 
1995; Wallace et al. 1996) 
Inguinal hernia repair 5-30 (Poobalan et al. 2003; Aasvang and 
Kehlet 2005; Kalliomäki et al. 2008) 
Cholecystectomy 10-50 (Middelfart et al. 1998) 
Caesarean section 12 (Nikolajsen et al. 2004) 
Orthopaedic surgery 10-60 (Johnsson and Thorngren 1989; 
Burkart et al. 1993; Brander et al. 
2003; Garcia et al. 2003; Harden et al. 
2003; Nikolajsen et al. 2006; Elson 
and Brenkel 2007; Martinez et al. 
2007; Lundblad et al. 2008) 
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 4.2 Risk factors of persistent postsurgical pain 
The risk factors of persistent postsurgical pain can be divided into patient factors 
and medical factors. Awareness of these factors can be useful in the prevention 
of postsurgical persistent pain. 
 
4.2.1 Medical risk factors for persistent postsurgical pain 
 
One medical risk factor above all others is the surgical procedure itself. This 
should be kept in mind, especially when patients are operated on for other 
reasons than illnesses - cosmetic surgery, sterilization etc. The possibility of 
chronic pain should be realized before making the decision to operate. The 
situation is the same with all types of surgery. Inguinal hernia repair is a typical 
procedure which may provoke persistent pain for previously painfree patients 
(Page  et  al.  2002)  and  by  contrast,  watchful  waiting  has  proven  to  be  a  safe  
method in this subgroup (Fitzgibbons et al. 2006). There are also studies 
showing that different surgical techniques used to treat the same illness offer a 
different safety profile concerning persistent pain (Macrae 2008). Laparoscopic 
herniorrhaphy, for instance, decreases the risk of nerve damage and pain 
compared to open surgery (Aasvang and Kehlet 2005). Yet, many new 
techniques have been taken into clinical practice without any long-term studies 
exploring the risk of persistent pain (Macrae 2001).  
Other medical factors include anaesthesia, perioperative analgesia and 
various treatments given. The hypothesis behind this is to inhibit 
hypersensitization during acute trauma and thus reduce the incidence of 
persistent pain. The data around this topic are controversial: some studies have 
shown a beneficial effect (Senturk et al. 2002; Tiippana et al. 2003; Nikolajsen et 
al. 2004), and some have not (Ho et al. 2002; Jensen and Andersen 2004; 
McCartney et al. 2004; Kalliomäki et al. 2008). The explanation may be that 
even a brief period of pain before or during operation is enough to sensitize the 
neurons and cause persistent pain (Macrae 2008). The effect of pre-existing pain 
on pre-emptive analgesia was tested in one prospective study in orthopaedic 
surgery and the result was clear: pre-emptive epidural analgesia was ineffective 
in the presence of pre-surgical pain (Aida et al. 2000). However, the impact of 
pre-emptive analgesia is far from established (Møiniche et al. 2002). 
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4.2.2 Patient risk factors for persistent postsurgical pain 
 
Patient-related risk factors for persistent postsurgical pain are genetic 
predisposition, pre-existing pain in the operated site or elsewhere, acute 
postsurgical pain, various psychosocial factors, young age, increased BMI or 
weight and female gender (Kehlet et al. 2006b; Macrae 2008). 
A genetic variation in the development of persistent pain, in the baseline 
sensitivity to pain and in the different responses to pharmacological treatments, 
has recently been under vigorous investigation (Belfer et al. 2004; Diatchenko et 
al. 2005; Stamer and Stuber 2007a; Stamer and Stuber 2007b; George et al. 
2008; Reimann et al. 2010). The genetic polymorphism behind the synthesis of 
catechol-O-methyltransferase (COMT) is known and low COMT activity in turn 
correlated  with  risk  of  persistent  pain  in  the  model  of  temporomandibular  joint  
pain in healthy female volunteers (Diatchenko et al. 2005). By contrast, high 
COMT activity was associated with higher pain ratings among patients evaluated 
3-5 months after shoulder surgery compared to those with low COMT activity 
(George et al. 2008). This disparity in the results shows one challenge of this 
kind  of  research:  totally  different  populations.  Healthy  volunteers  cannot  be  
compared with patients with pre-existing pain. In 2006 Tegeder et al. 
demonstrated that a certain human haplotype responsible for the synthesis of 
GTP cyclohydrolase 1 (Dopa-responsive dystonia) was associated with reduced 
persistent pain after lumbar discectomy (Tegeder et al. 2006). GTP 
cyclohydrolase is known to be essential in the production of tetrahydrobiopterin, 
which in turn is a cofactor for the synthesis of catecholamines, serotonin and 
nitric oxide. This makes GTP cyclohydrolase an important enzyme in the 
development of peripheral neuropathic and inflammatory pain. This haplotype 
was found in 15.4 % of patients (Tegeder et al. 2006). The voltage-gated sodium 
channel type 9 ? in peripheral neurons is responsible for the potential production 
and is encoded by the gene whose mutations cause different phenotypes in pain 
sensations - from total inability to feel pain to paroxysmal extreme pain disorder 
(Drenth and Waxman 2007; Reimann et al. 2010). Other candidate genes listed 
to be investigated are those responsible for the production of interleukin 6 and 
1ß, neuronal nitric oxide synthase and tumor necrosis factor ? (Belfer et al. 
2004). The aim in the future is to find a correlation between the single nucleotide 
polymorphism and the risk of developing persistent pain after primary injury. 
Pre-operative pain has in general increased the risk of persistent pain after 
surgery. This was clearly shown with phantom limb pain after amputation 
(Nikolajsen et al. 1997c). The more intense and enduring the preamputation pain, 
the more severe was phantom pain (Nikolajsen et al. 1997c). This led to several 
studies where preamputation pain was properly treated (Nikolajsen et al. 1997a; 
Nikolajsen et al. 1997b). Unfortunately, the incidence of phantom limb pain 
could not be reduced after the first positive study (Bach et al. 1988); the 
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hypersensitization had already occurred. Keller et al. showed that preoperative 
use of narcotics increased the risk of persistent pain after thoracotomy (Keller et 
al. 1994) and preoperative pain was also a risk factor for persistent pain in 
inguinal herniorraphy (O'Dwyer et al. 2005; Kalliomäki et al. 2008) and in total 
knee replacement (Brander et al. 2003;Lundblad et al. 2008). On the other hand, 
pre-existing pain was not a risk factor for persistent pain in cholecystectomy 
(Middelfart et al. 1998) or in hip replacement (Nikolajsen et al. 2006). 
Acute postoperative pain is more evidently associated with persistent 
postsurgical pain than preoperative pain. The results from trials concur. The 
association was first published in patients recovering from thoracotomy (Kalso et 
al. 1992), but postoperative pain has also been found as a risk factor for 
persistent pain after coronary artery bypass grafting (Bruce et al. 2003), hernia 
repair (Aasvang and Kehlet 2005), breast cancer surgery (Poleshuck et al. 2006), 
orthopaedic surgery (Nikolajsen et al. 2006) and Caesarean section (Nikolajsen 
et al. 2004). 
Certain pain conditions: fibromyalgia, irritable bowel syndrome, irritable 
bladder, Raynaud’s syndrome, migraine and backache, are known to be related 
to elevated risk of persistent pain after injury (Courtney et al. 2002; Wright et al. 
2002; Brandsborg et al. 2008). The explanation may be found when the genetic 
polymorphism behind all these conditions is identified (Macrae 2008). 
Advanced age seems to reduce the risk of persistent pain after surgery. There 
are several studies in which younger patients were more prone to developing 
persistent pain after hernia repair (Poobalan et al. 2003; Aasvang and Kehlet 
2005; Kalliomäki et al. 2008) or breast cancer surgery (Smith et al. 1999; 
Poleshuck  et  al.  2006).  This  contradicts  the  finding  of  age  as  a  risk  factor  for  
postherpetic neuralgia after acute herpes virus infection (Jung et al. 2004). The 
baseline prevalence of chronic pain is also higher in older people, which was 
shown in a large population study (Saastamoinen et al. 2005). Age over 50 years 
increased the risk of persistent pain at one year after knee arthroscopic procedure 
(Rosseland et al. 2008). This can be explained by the higher overall prevalence 
of chronic pain in this population rather than by the arthroscopy itself.  
Weight  and  BMI may be  risk  factors  for  persistent  pain,  at  least  in  hip  and  
knee arthroplastic surgery (Bagge et al. 1991). There is little evidence to support 
this hypothesis because BMI or weight has not been taken account in risk 
analysis. After revision total hip arthroplasty high BMI (30kg/m2 or over) was 
associated with persistent pain (Singh and Lewallen 2009). 
Female gender in turn is a well documented risk factor for persistent pain 
(Rosseland and Stubhaug 2004; Kehlet et al. 2006a; Bernardes et al. 2008; 
Macrae 2008; Singh and Lewallen 2009).  
Psychiatric disorders assumed to be the risk factors for persistent postsurgical 
pain are depression and anxiety. This association is difficult to investigate 
because of the bidirectional causality of these states. Several large 
epidemiological studies have shown that depression and anxiety overall predict 
the onset of chronic pain syndromes (Gureje et al. 2001; Harkness et al. 2004) 
but on the other hand, chronic pain at baseline also predicts subsequent 
depression or anxiety (Gureje et al. 2001). The evidence from surgical patients is 
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scarce. Tasmuth et al. showed that patients who suffered from persistent pain one 
year after breast cancer operation were more likely to be depressive than those 
who were painfree (Tasmuth et al. 1996). Psychosocial risk factors for persistent 
pain have gradually been taken into account. In the 1990s studies were 
conducted where neuroticism (Jess et al. 1998) and introverted personality 
(Borly et al. 1999) were found to be risk factors for persistent pain after 
cholecystectomy. In the 2000s investigators took a greater interest in the 
psychosocial factors behind pain and rehabilitation. Preoperative depression and 
anxiety were both associated with persistent pain after both knee replacement 
(Brander et al. 2003; Harden et al. 2003) and hip replacement (Rolfson et al. 
2009). Anxiety was not tested but preoperative depression was also a risk factor 
for persistent pain after revision total hip arthroplasty in a study by Singh et al. 
(Singh and Lewallen 2009). Fear of the long-term consequences of the operation 
was associated with persistent pain in a large prospective on the predictors of 
long-term unfavourable surgical outcomes (Peters et al. 2007).  
By contrast, there are many studies which show that psychosocial factors 
have predicted subsequent acute postoperative pain (Taenzer et al. 1986; 
Tacconelli et al. 2002; Granot and Ferber 2005; Katz et al. 2005; Papaioannou et 
al. 2009). Severe acute postoperative pain in turn has consistently been found to 
be a risk factor for persistent pain (Kalso et al. 1992; Bruce et al. 2003; 
Nikolajsen et al. 2004; Aasvang and Kehlet 2005; Nikolajsen et al. 2006; 
Poleshuck et al. 2006). Therefore we can assume that associations between 
psychosocial factors and persistent pain are also waiting to be found. 
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Aims of the study 
The  aim  of  this  thesis  was  to  study  therapy  of  postoperative  pain  and  the  
prevalence and risk factors of persistent pain after surgery. The specific aims 
were: 
 
 
1. To study whether parecoxib 80mg is a more appropriate dose than 
40mg for postoperative pain relief in patients undergoing laparoscopic 
cholecystectomy (I). 
 
2. To study whether etoricoxib 120mg either alone or in combination 
with paracetamol 1000mg given in premedication reduces additional 
postoperative pain treatment in patients undergoing laparoscopic 
cholecystectomy (II). 
 
3. To ascertain the renal adverse effects of the COX-2 inhibitor, 
parecoxib 80mg, by measuring the sensitive markers of both tubular 
and glomerular damage in patients undergoing laparoscopic 
hysterectomy (III). 
 
4. To study whether the type of operation (primary, bilateral, revision) 
affects the development of persistent pain after knee arthroplasty and 
to  reveal  the  overall  degree  and  risk  factors  of  persistent  pain  after  
knee arthroplasty with a questionnaire in a large, register-based cross-
sectional prevalence study (IV). 
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Patients and methods 
The studies were approved by the ethic committees of the participating 
institutions (I-IV) and the National Agency for Medicines (I-III).  
 
1. Patients 
Written informed consent was obtained from each patient. 
Studies I-III were prospective, randomized, blinded and placebo controlled. The 
randomization procedure was guaranteed by computer-generated random 
numbers. Double-blindness was in turn guaranteed by arranging the delivery of 
investigational medicine through a special nurse. The dose-response Studies, I 
and II were so-called one-centre studies, but Study III was conducted in two 
centres.  
The inclusion criteria differed slightly between the prospective Studies, I-III. 
Congestive heart disease, angina pectoris and cerebrovascular circulatory 
symptoms were included in the exclusion criteria in the ongoing Study II after 
alarming reports about thrombotic events in other published trials. The inclusion 
and exclusion criteria of Studies I-III are collected in Table 4.  
Study IV was a questionnaire-based, cross-sectional prevalence study. 
Patients who had undergone knee arthroplasty during the period from 1 
September 2002 to 28 February 2004 were recruited from the arthroplasty 
registry of an arthroplasty specialized hospital. The total number of patients 
receiving the questionnaire was 855. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
Table 4. Inclusion and exclusion criteria of Studies I-III 
 
 Study I Study II Study III 
Inclusion criteria Laparoscopic 
cholecystectomy, 
ASA I-II, 
30-60 years,  
60-100kg 
 
Laparoscopic 
cholecystectomy, 
ASA I-III,  
16-70 years 
 
Laparoscopic 
hysterectomy, 
 ASA I-II,  
30-60 years,  
50-80kg 
 
Exclusion criteria allergy to aspirin-
like drugs/ 
sulphonamide, 
bronchial asthma, 
liver or renal 
dysfunction, 
peptic ulcer, 
bleeding disorder, 
pregnancy, 
substance abuse, 
chronic pain 
BMI>40kg/m2, 
allergy to aspirin-
like drugs, 
bronchial asthma, 
liver or renal 
dysfunction, 
peptic ulcer, 
bleeding disorder, 
pregnancy, 
substance abuse, 
chronic pain, 
congestive heart 
disease, angina 
pectoris and 
cerebrovascular 
circulatory 
symptoms 
allergy to aspirin-
like drugs/ 
sulphonamide, 
bronchial asthma, 
liver or renal 
dysfunction, 
peptic ulcer, 
bleeding disorder, 
pregnancy, 
substance abuse, 
chronic pain 
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2. Anaesthesia and fluid treatment 
General anaesthesia was standardized in Studies I-III. Induction was with 
fentanyl 2µg/kg, propofol 2-3mg/kg and rocuronium 0,6mg/kg. An equal amount 
of fentanyl was given about 3 minutes before skin incision. A semi-closed 
breathing  system  with  fresh  gas  flow  of  2-3  l/min  was  used.  Anaesthesia  was  
maintained with sevoflurane in air/O2 66/34% and adjusted to keep systolic 
blood pressure level between 85–130 mmHg (sevoflurane end-tidal 
concentration, about 2%). Muscle relaxation was maintained with rocuronium. 
EtCO2 was kept between 5.0 and 5.5 % by adjusting the ventilation. Residual 
neuromuscular block was antagonized with neostigmine and glycopyrrolate. 
Regional anaesthesia, i.e. wound infiltration with 5 mg/ml bupivacaine with 
adrenaline, was used only in Study II. 
Anaesthesia for patients in Study IV was produced mainly by spinal block 
but an epidural catheter was inserted to ensure anaesthesia in prolonged cases.  
Fluid treatment was equal in the dose-response studies (I-II). Ringer's 
acetated solution was administered perioperatively and then followed by a liter 
of a mixture of 0.3% NaCl in 5% glucose in the next 12 hours. In Study III with 
renal markers, fluid treatment was designed to be more restricted than liberal to 
support the stress model for the kidneys. Ringer's acetated solution, bolus of 
5ml/kg followed by 5ml/kg/h, was administered during surgery and followed 
directly with one liter of a mixture of 0.3% NaCl in 5% glucose in the next 12 
hours. Five hundred ml of 4% gelatine solution was used only if surgical blood 
loss was over 400ml. Fluid administration was not evaluated in Study IV. 
3. Pain assessment, pain treatment and premedication 
The protocols for pain assessment and rescue pain treatment were quite similar 
in all the prospective studies, I-III. During the preanaesthetic round the patients 
were instructed in the use of a visual analogue scale (VAS, 0 - 10). Pain intensity 
at rest, during coughing, and during leg elevation were assessed using VAS in 
the preoperative round, on arrival in the operating theatre, at 1 h, 2 h, 4 h, 6 h, 8 
h, 10 h, and 20 h after the end of surgery. The patients were also asked to 
evaluate the worst pain score at rest encountered during the previous period at 
two hours and at 20 hours after the end of surgery. At the end of the observation 
period the patients were asked to express their opinion concerning the efficacy of 
the  pain  relief  treatment  (0  =  excellent,  1  =  good,  2  =  unknown,  3  =  fair,  4  =  
poor).  
The patients were instructed preoperatively and assisted postoperatively in 
the use of the patient-controlled analgesia device (PCA), programmed to deliver 
50 µg of fentanyl during two minutes. The lockout time was 5 min, and the 
maximum dose was 10 ml/h (= 500 µg) during the first 2 hours in the recovery 
room and 5 ml/h (= 250 µg) on the ward until 20 hours after the end of surgery. 
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During emergence from anaesthesia, the recovery room nurses were allowed to 
give additional fentanyl boluses via the PCA device at the patients’ request. The 
time interval between the end of surgery and the first bolus of fentanyl delivered 
by  the  PCA  device  was  recorded.  Additional  need  for  pain  treatment  was  
evaluated by the frequency and by the amount of PCA delivered in fentanyl 
boluses during the first 20 postoperative hours. 
The medications studied were parecoxib 40mg (I) and 80mg (I, III), 
etoricoxib 120mg (II) and paracetamol 1000mg (II). Intravenously administered 
parecoxib was given at the end of anaesthesia in Study I, but before the induction 
of anaesthesia in Study III. Orally administered etoricoxib alone or combined 
with  paracetamol  was  given  as  premedication.  Premedication  was  otherwise  
similar in all prospective studies, oxazepam 15mg orally, but the placebo-group 
was given oxycodone 10mg orally in Study III to ensure efficient pain relief. 
Pain  assessment  in  Study  IV  was  performed  by  the  questionnaire,  which  is  
presented later. Acute pain relief until the first postoperative day was ensured by 
epidural analgesia combined with paracetamol and NDSAID if appropriate. 
Epidural analgesia was replaced with opioids. 
4. Adverse events and laboratory samples 
The patients in Studies I-II were asked about nausea using VAS during the 
preoperative round, on arrival in the operating theatre and at 1 h, 2 h, 4 h, 6 h, 8 
h, 10 h, and 20 h postoperatively. At the same time points, the patients were also 
asked about the type and degree (VAS) of other possible adverse effects of any 
kind. The antiemetics used were recorded at 2 h and 20 h postoperatively 
Laboratory samples were taken in Study III. The samples for the analyses of 
serum and urine were collected during the induction of anaesthesia, 2 hours 
thereafter,  2  hours  after  anaesthesia  and  on  the  first  postoperative  day.  The  
samples of serum creatinine, urea, sodium, potassium, ?-1-microglobulin and 
cystatin  C  were  analysed  on  the  next  working  day.  Samples  for  GST  were  
conserved in a tube with stabilizer (containing mertiolate and azide) and stored at 
-20°C before analysis. All these samples were stored and analysed according to 
good laboratory practice by the laboratory of Tampere University Hospital. 
5. Questionnaire 
The questionnaire, used in Study IV, was mailed to all patients with a prepaid 
return  envelope  in  July  2004.  In  case  of  no  reply,  one  reminder  was  sent.  The  
demographics were elicited. All the other questions concerned pre- and 
postoperative pain. The duration of preoperative pain and the intensity of 
postoperative pain during the first week (mild, moderate, severe, unbearable) 
were elicited. If the patient still had pain when receiving the questionnaire, pain 
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intensity at rest and during exercise was evaluated. The degree of disturbance of 
daily  life  and  sleep  due  to  pain  (none,  mild,  moderate,  severe)  and  the  
consumption of analgesics for persistent pain in the operated knee were elicited. 
The questionnaire is presented in the Appendix. The time interval between the 
surgery and the questionnaire was minimum 4 months and maximum 22 months. 
6. Statistics 
6.1 Sample size estimation 
The  sample  size  estimation  in  Study  I  was  based  on  our  hypothesis  that  
parecoxib reduces the need for postoperative pain treatment during the first 20 
postoperative hours to the same degree as traditional nonsteroidal anti-
inflammatory drugs. We calculated that with 20 patients/group the sample size 
would be sufficient to detect a difference of 40 % in the overall number of 
fentanyl boluses during the first 20 postoperative hours between the group P80 
and the control group (? = 0.05, power = 80%). The sample size estimation in 
Study II was based on the assumption that etoricoxib reduces the need for 
opioids by 33%. Thus, with ? = 0.05 and power = 80%, the sample size was 23 
patients in each group. In Study III we assumed that the novel renal markers 
would be more sensitive than earlier ones to show if any clinically significant 
renal damage had occurred. A sample size of thousands would have been needed 
to find differences in outcomes such as increased creatine level, because renal 
adverse events with COX-2 inhibitors have been reported to occur in less than 
2% of the population. Study IV was not an intervention study. The questionnaire 
was sent to all patients operated on and the number of patients responding was 
sufficient for risk analysis. 
6.2 Data analysis 
The numerical variables were reported by means with standard deviations or by 
medians and quartiles depending on data distribution. The categorical variables 
were presented as absolute and relative frequencies. The significance tests used 
in Studies I-III are listed in Table 5. P< 0.05 was considered statistically 
significant. 
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Table 5. Significance testes and programmes used in Studies I-III 
  
 Study I Study II Study III 
Demographic 
data 
ANOVA ANOVA t-test 
Categorized 
data 
Pearson’s ?2 Pearson’s ?2 Pearson’s ?2 
Data of 
fentanyl 
consumption, 
VAS scores, 
laboratory 
samples 
(skewed 
distribution) 
Kruskall-
Wallis 
Kruskall-
Wallis 
 
Mann-
Whitney 
Statistical 
programme 
SPSS for 
Windows 
11.5 
SPSS for 
Windows 
11.5 
SPSS for 
Windows 
14.02 
 
The data from the returned questionnaires and from the hospital registry in Study 
IV were analysed using multiple logistic regression analysis. The dependent 
variable  was  pain  at  the  time  of  the  questionnaire.  The  explanatory  variables  
were treatment, age (centred at age 70 and including a quadratic term), gender, 
body mass index, pain score and duration prior to surgery, pain score during the 
first  week  after  surgery,  type  of  prosthesis  and  diagnosis.  The  results  of  the  
univariate and multivariate logistic regression analyses are presented as odds 
ratios with 95% confidence intervals. Logistic regression was used instead of 
linear regression because the object of the study - persistent pain or not - was 
binominal. All these computations were done with R Development Core Team, 
2008. 
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Results 
1. Patient recruitment and baseline characteristics 
Patients  involved  in  the  prospective  Studies  I-III  are  shown  as  a  flow  chart  in  
Figure  5.  Nine  patients  were  excluded  from  Study  I  for  the  following  reasons:  
laparoscopic operation turned into open cholecystectomy in four patients; local 
anaesthetics were used on one patient, one foreign patient was unable to answer 
the questions, two patients did not fit the protocol (weight >100kg) and one 
patient was rejected because of an extremely difficult and time consuming 
operation (>120min). Three patients were excluded from Study II for the 
following reasons: laparoscopic operation turned into open cholecystectomy in 
two patients and macroscopic hepatic cirrhosis, diagnosed at the beginning of the 
laparoscopy, also caused the cancellation of the operation. In addition to these 
three patients, VAS scores for postoperative pain and PONV were missing for 6 
patients.  
Baseline  data  from  the  prospective  Studies  I-III  are  shown  in  Table  6.  The  
variables are expressed in percentiles, means with standard deviations (±SD) or 
medians and quartiles (Q1,Q3). Appropriate significance tests were applied, but 
the groups were statistically equal. The total population of Study IV is presented 
in Table 7. 
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Figure 5. Flow chart of patients in Studies I-III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total 178 
patients 
Study I: 
73 
patients 
Study II: 
75 
patients 
Study III: 
30 
patients 
Placebo:  
 20 patients 
Parecoxib 
80mg: 
21 patients 
    72 
patients 
included 
Parecoxib 
40mg:  
23 patients 
Pareco-
xib 
80mg: 
15 
patients 
Placebo 
15 
patients 
9 patients 
 excluded 
3 patients 
excluded 
Etoricoxib 
120mg: 
24 patients 
Placebo: 
23 patients 
Etoricoxib 
120mg+ 
Paracetamol 
1g:  
25 patients 
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Table 6. Baseline data in Studies I-III 
 
 Px40 
(n=23) 
Px80 
(n=21) 
PlaI 
(n=20) 
E 
(n=24) 
E+P 
(n=25) 
PlaII 
(n=23) 
Px 
(n=15) 
PlaIII 
(n=15) 
 
Age (year) 45±9 44±12 41±10 46±12 45±11 45±9 49±8 51±5 
Gender 
(Female%) 
74 81 70 79 80 70 100 100 
Weight 
(kg) 
77±14 77±12 75±11 79±14 84±12 78±15   
BMI 
(kg/m2) 
      24.8±2.9 25.2±2.4 
ASA 
I/II/III (%) 
48/52/0 62/38/0 60/40/0 38/54/8 40/56/4 48/39/13 67/33/0 67/33/0 
surgery 
duration 
(min) 
63±37 56±24 54±25 55 
(44,75) 
63 
(48,68) 
72 
(47,91) 
103±28 103±34 
Creatinine 
clearance 
(ml/min) 
- - - - - - 100.7± 
20.4 
105.9± 
23.3 
Study I: Px40= parecoxib 40mg, Px80=parecoxib80mg, PlaI=placebo 
Study II: E=etoricoxib 120mg, E+P= etoricoxib 120mg+paracetamol 1g, 
PlaII=placebo 
Study III: Px=Parecoxib80mg, PlaIII=placebo 
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Table 7. Baseline data in Study IV 
 
 n (%) mean ±SD 
Total population 855   
Responders 562 (65.7)  
*Age (years)  69±9 
*BMI (kg/m2)  29.1±4.4 
*Female gender  396 (70.5)  
*Diagnosis   
osteoarthritis 535 (95.2)  
rheumatoid arthritis 18 (3.2)  
unknown   9 (1.6)  
*Operation   
primary arthroplasty 433 (77.0)  
bilateral arthroplasty  95 (16.9)  
revision arthroplasty  34 (6.1)  
*Presurgical pain score   
no pain or mild   40 (7.1)  
moderate, occasional 271 (48.2)  
moderate continuous 200 (35.6)  
severe   44 (7.8)  
unknown     7 (1.3)  
*Presurgical duration of 
pain 
  
?12months   51 (9.1)  
>12months 493 (87.7)  
unknown   18 (3.2)  
*Early postsurgical pain 
score 
  
mild 151 (26.9)  
moderate 244 (43.4)  
severe 135 (24.0)  
unbearable   24 (4.3)  
unknown     8 (1.4)  
*variables were assumed to be the risk factors for persistent pain  
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2. Analgesic efficacy 
The analgesic efficacy of the investigational drugs was studied in Studies I and II 
by comparing data from cumulative fentanyl consumption delivered from the 
PCA-device. Pain scores expressed by VAS were evaluated. Global satisfaction 
in pain treatment was also analysed. 
2.1 Opioid sparing effect  
Opioid sparing effect was evident with both etoricoxib treated groups, but 
adding paracetamol to premedication or giving parecoxib alone at the end of 
surgery did not show any opioid sparing effect.  
 
Table 8. Cumulative postoperative fentanyl consumption, µg/kg (medians 
(Q1,Q3)) during the first 20 hours in Studies I and II 
 
 1h 2h 4h 10h 20h 
Px40 1.2(0.6,2.3) 1.9(1.3,3.1) 3.2(1.9,5.0) 3.9(3.2,8.3) 5.2(3.9,10.9) 
Px80 0.6(0.6,1.2) 1.2(0.6,3.1) 2.6(1.2,3.7) 4.5(2.8,5.2) 5.8(3.6,7.6) 
PlaI 1.3(0.7,2.0) 2.7(1.7,3.7) 3.3(2.7,7.3) 5.3(3.3,10.0) 6.7(4.0,14.7) 
E 0.02(0.01,0.03) 0.03*(0.02,0.06) 2.3*(1.5,4.2) 4.2*(2.4,6.3) 6.8*(3.7,8.6) 
E+P 0.02(0.01,0.04) 0.04*(0.03,0.06) 2.5*(2.0,5.0) 3.9*(2.5,7.4) 7.0*((4.3,9.7) 
PlaII 0.04((0.01,0.07) 0.05(0.03,0.1) 5.3(2.5,6.6) 7.5(4.7,10.3) 8.8(7.2,15.1) 
 
Px40= parecoxib 40mg, Px80=parecoxib80mg, PlaI=placebo 
E=etoricoxib 120mg, E+P= etoricoxib 120mg+paracetamol 1g, PlaII=placebo 
*p<0.05 when compared to placebo and tested by Kruskall-Wallis. 
2.2 Pain scores 
Pain scores were tested at rest, during coughing and leg elevations 1h, 2h, 4h, 6h, 
8h 10h and 20h postoperatively. Especially at night, there were missing values 
disturbing the analysis. VAS scores could be analysed in 130 patients out of total 
136 patients. The scores also remained low (VAS ? 6) in the placebo groups. 
There were no clinically or statistically significant differences between the 
groups when tested with nonparametric test.  
The  worst  pain  on  the  ward  was  also  evaluated  by  VAS  score.  Patients  
treated with parecoxib 80mg at the end of surgery evaluated their worst pain on 
the ward significantly lower than did the placebo group (p= 0.014). Mean values 
with standard deviations for VAS scores were 3.9±1.9 and 5.8±3.0 respectively.  
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2.3 Global evaluation of analgesia 
Almost all patients evaluated their analgesia as excellent or good when asked at 
the end of the study. Nevertheless, there was a clear tendency to lower values in 
evaluations in the placebo groups.  
 
Table 9. Global evaluation of analgesia (n(%)) 
 
Groups Excellent Good Unknown Fair Poor 
Px40 17(73.9) 5 (21.7) 1 (4.4) 0 0 
Px80 14 (66.7) 7 (33.3) 0 0 0 
PlaI 9 (42.8) 6 (28.6) 4 (19.0) 1 (4.8) 1 (4.8) 
E 16 (66.7) 6 (25.0) 2 (8.3) 0 0 
E+P 19 (76.0) 3 (12.0) 3 (12.0) 0 0 
PlaII 9 (39.1) 9 (39.1) 5 (21.8) 0 0 
3. Adverse events 
Adverse events were recorded in VAS parallel to pain scores in Studies I and II. 
Nausea and vomiting were equally distributed at each time point between the 
groups. The only clinically and statistically significant difference was found in 
the proportion of patients whose highest PONV score on the ward was more than 
three in VAS (p=0.033). This proportion was 5% with etorixocib and 
paracetamol treated patients, 18% with etoricoxib treated patients and 33% with 
placebo treated patients. Antiemetic doses did not differ between the groups.  
Other adverse effects mentioned were headache, dizziness and blurred vision, 
but these were small in number and also equally distributed between the groups. 
Study III concentrated on renal adverse events with parecoxib. The results are 
presented in Tables 10a and 10b. There were few statistically but no clinically 
significant differences between groups in any renal measurement during the 
study period. The values of U-?-GST/U-crea were increased two hours after the 
start of anaesthesia in both groups. The increase was also statistically significant 
(Mann-Whitney test): p= 0.013 in the parecoxib and p= 0.033 in the placebo 
group when compared to baseline levels. The number of patients is mentioned at 
each measurement in each group, because data was either missing or the outliers 
were omitted (seven measurements). One third of the measurements of urinary ?-
1-microglobulin was undetectable (<5.2mg/L) making statistical analysis 
impossible. However, there was no clinical difference between the groups in 
urinary ?-1-microglobulins. The urinary output during the first four hours was 
small in volume but there was no difference between the groups. 
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Table 10a. Renal measurements (n, median (Q1,Q3)) with normal values
   
Measurement, 
group 
 
Baseline  
 
2h after 
induction 
2h after end of 
anaesthesia 
1. POD 
S-crea  <95 µmol/l   
parecoxib 14, 
 61(58,67) 
14,  
60(57,69) 
14, 
63(56,71) 
13,  
57(55,70) 
placebo  14, 
62(54,66) 
14,  
61(49,64) 
14, 
 59(52,64) 
12, 
 56(47,60) 
S-urea  2.6-6.4 mmol/l   
parecoxib 15, 
 3.7(2.8,4.8) 
15, 
3.3(2.9,4.0) 
15, 
 3.3(3.0,4.8) 
13, 
2.4(2.2,3.8) 
placebo 14, 
4.2(3.6,5.4) 
15, 
4.0(3.5,5.0) 
15,  
4.2(3.5,5.0) 
12, 
 2.7(2.3,3.1) 
S-CysC  <1.4-1.5 mg/l 
parecoxib 15, 
0.74(0.66,0.85) 
15, 
0.67(0.55,0.76) 
15, 
0.66(0.57,0.83) 
13, 
0.68(0.60,0.78) 
placebo 15, 
0.71(0.64,0.84) 
15, 
 0.65(0.56-0.78) 
15, 
0.66(0.56,0.72) 
12, 
0.67(0.55,0.78) 
S-K   3.5-4.5 mmol/l   
parecoxib 15, 4.1(4.0,4.3) 14, 4.1(4.0,4.4) 12, 4.1(4.0,4.6) 13, 4.0(3.8,4.2) 
placebo 14, 4.2(4.0,4.2) 15, 4.2(4.0,4.4) 14, 4.0(3.9,4.2) 12, 3.6(3.4,3.8) 
S-Na 137-145 mmol/l 
parecoxib 15, 
140(139-142) 
15, 
139(138,141) 
15,  
140(137,141) 
13, 
139(136,142) 
placebo 14, 
139(138,141) 
15, 
140(138,141) 
14,  
139(138,141) 
11, 
137(136,139) 
 
Table 10b. Urinary renal measurements (n, median (Q1,Q3)) with normal   
     values  
 
 Baseline 2h after 
induction 
2h after end of 
anaesthesia 
1.POD 
U-?GST/u-crea 0.10-1.93 µg/mmol 
parecoxib 14, 
2.07(0.33,2.46) 
13, 
 0.42(0.05,0.77) 
13, 
0.15(0.05,0.67) 
10, 
 0.50(0.01,0.98) 
placebo 13, 
0.62(0.17,1.75) 
13, 
 0.15(0.02,0.93) 
12, 
0.13(0.04,0.98) 
11, 
 0.58(0.15,0.99) 
U-?GST/u-crea 0.25-7.41 µg/mmol 
parecoxib 14, 2.8(1.2,6.5) 13, 12.2(1.9,36.6)* 13, 3.1(0.3,7.1)* 10, 2.1(0.6,3.7) 
placebo 13, 4.5(1.6,5.5) 13,17.3(11.8,22.9)* 12, 2.1(0.7,3.6)* 10, 1.7(0.9,4.0) 
POD=postoperative day 
* p<0.05 when compared to baseline measurement and tested by Mann-Whitney 
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4. Persistent pain 
Persistent postsurgical pain was the research object of Study IV. The results are 
divided  into  two  sections:  prevalence  and  intensity  of  persistent  pain  and  risk  
factors for persistent pain. 
4.1 Prevalence and intensity of persistent pain 
The prevalence of persistent pain after knee arthroplasty was 21.5% at rest and 
29.8% during exercise. Of the patients, 35.1 % suffered from pain disturbing 
daily life while 24.3 % of the patients reported disturbances of sleep because of 
pain. The proportion of patients still using analgesics because of pain in the 
operated knee was 43.3%. The intensity of pain at rest and during exercise is 
shown in Figures 6 and 7. Effect on daily life and sleep are presented in Figures 
8 and 9. 
Figure 6. Pain at rest
mild
moderate
severe
 
Figure 7. Pain during exercise
mild
moderate
severe
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Figure 8. Disturbance of daily life
mild
moderate
severe
 
Figure 9. Disturbance of sleep
mild
moderate
severe
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4.2 Risk factors for persistent pain 
 
Table 11. Analysis of risk factors predicting persistent pain after knee 
arthroplasty 
 
Variable Pain 
Yes/No 
Univariate 
analysis 
OR(95%CI) 
Multivariate 
analysis 
OR(95%CI) 
Operation:    
Primary 101/304   
Bilateral 22/70 0.95(0.55-1.58) 0.89(0.48-1.56) 
Revision 7/22 0.96(0.37-2.20) 1.09(0.37-2.89) 
Age   0.98(0.96-1.00) 1.01(0.99-1.04) 
Age, squared and 
centred at 70 years  
 1.0027(1.0007-1.0048) 
BMI  1.01(0.97-1.06)  
Gender:    
Male 25/128   
Female 105/268 2.00(1.25-3.31) 1.90(1.14-3.28) 
Diagnosis:    
Rheumatoid arthritis 6/18   
Osteoarthritis 124/378 0.98(0.40-2.76)  
Presurgical pain score:    
No pain or mild 7/31   
Moderate, occasional 59/196 1.33(0.59-3.43)  
Moderate, continuous 48/139 1.53(0.66-3.98)  
Severe 15/24 2.77(1.00-8.26)  
Presurgical duration of 
pain 
   
?12 months 5/42   
>12 months 122/342 3.00(1.27-8.82) 2.84(1.14-8.65) 
Early postsurgical pain 
score: 
   
Mild 11/128   
Moderate 50/179 3.25(1.69-6.80) 3.11(1.59-6.62) 
Severe 56/74 8.81(4.50-18.70) 8.17(4.04-17.83) 
Unbearable 13/11 13.75(5.09-
39.10) 
10.69(3.63-
32.63) 
. 
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Severe presurgical pain seemed to be a risk factor for persistent pain 
according to the univariate analysis. Backward selection of multivariate logistic 
regression analysis left only age and its quadratic term, gender, the duration of 
pain prior to surgery and early postoperative pain for the final model. The type of 
operation was kept in the model to test our primary hypothesis - the degree of 
primary injury is associated with persistent pain. ORs for continuous variables 
(age, quadratic term of age, BMI) refer to one unit change. 
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Discussion 
1. Analgesic efficacy of COX-2 inhibitors 
Parecoxib failed to prove any significant opioid sparing effect in Study I. By 
contrast, the opioid sparing effect of etoricoxib was seen almost throughout 
Study II. According to other published studies parecoxib should have had some 
analgesic effect when compared to the placebo. Perioperatively administered 
parecoxib  has  spared  opioid  requirements  after  cholecystectomy  (Gan  et  al.  
2004), hysterectomy (Tang et al. 2002; Ng et al. 2003), total knee (Hubbard et al. 
2003; Reynolds et al. 2003) or hip arthroplasty (Camu et al. 2002; Malan et al. 
2003) and coronary artery bypass surgery (Ott et al. 2003). Statistical 
significance was reached by increasing the size of the study groups (Camu et al. 
2002; Hubbard et al. 2003; Malan et al. 2003; Ott et al. 2003; Reynolds et al. 
2003; Gan et al. 2004) or using parametric test although the normality of the data 
was questionable (Tang et al. 2002). Difference in opioid consumption was 
around 30 % in all these studies, which can be regarded as clinically significant 
(Merskey 1994). The situation is different when analgesic efficacy is compared 
with different pain scores. The statistical difference persists (Camu et al. 2002; 
Ott et al. 2003; Reynolds et al. 2003; Gan et al. 2004; Beaussier et al. 2005) but 
the clinical importance of the values is difficult to evaluate without absolute 
numbers (Camu et al. 2002; Ott et al. 2003; Reynolds et al. 2003; Beaussier et al. 
2005). Our study showed the greatest decrease in opioid consumption (50%) 
during the first two postoperative hours, but nonparametric test did not give 
statistical significance to that difference between parecoxib 80mg and placebo 
treated groups. At four hours the difference was reduced to 20% and after ten 
hours to 15 %. This is in line with the pharmacodynamic profile of parecoxib. 
Administration twice a day would have offered a more stable analgesic 
concentration and probably also analgesic efficacy. 
Etoricoxib showed an opioid sparing effect respectively of 50% to 20% from 
two to 20 postoperative hours in our study. This is in line with other published 
studies on the perioperative use of etoricoxib. Compared to placebo, etoricoxib 
has proved its efficacy in arthroscopic acromioplasty (Toivonen et al. 2007), 
thyroid surgery (Smirnov et al. 2008), knee or hip arthroplasty (Rasmussen et al. 
2005) and in several dental impaction pain models (Malmstrom et al. 2003; 
Chang et al. 2004). 
The overall evaluation of analgesia was favorable to coxibs, which has been 
demonstrated in other studies, too (Hubbard et al. 2003; Ott et al. 2003; 
Reynolds et al. 2003; Beaussier et al. 2005; Rasmussen et al. 2005). Beaussier et 
 
 
55
al. were even able to show the superiority of parecoxib 40mg over propacetamol 
2g twice during the first 12 hours after open herniorraphy (Beaussier et al. 2005) 
Combining paracetamol 1g with etorixocib as premedication did not result in 
any further reduction in fentanyl consumption in our study. The action of 
paracetamol was limited to the first hours after surgery because of its short half-
life. At the same time, opioids used and local anaesthesia infiltrated during the 
operation reduced the need for any additional pain treatment during those first 
postoperative hours hiding any analgesic effect of paracetamol. The loading dose 
of paracetamol of 2g might have been more efficacious, because at least after 
dental  surgery  it  increased  both  the  extent  and  the  duration  of  analgesia  of  
paracetamol (Juhl et al. 2006). 
There are two systematic reviews with contradictory conclusions regarding 
the effect of paracetamol in clinical pain relief when combined with NSAIDs 
(Hyllested et al. 2002; Rømsing et al. 2002). Both reviewers found very limited 
data concerning the combination. Hyllested et al. opted to combine paracetamol 
with NSAIDs while Römsing et al. found no evidence to support such a practice. 
The only supportive study evaluated by analgesic sparing effect was in dental 
surgery, where paracetamol 1g added to diclofenac 100mg was more effective 
than diclofenac alone during the first eight hours (Breivik et al. 1999). In 
addition, there are animal studies (Miranda et al. 2006) and studies with healthy 
volunteers (Romundstad et al. 2006) showing a synergistic interaction between 
paracetamol and NSAIDs. 
2. Safety of COX-2 inhibitors 
The safety of COX-2 inhibitors has been under discussion for years. Both the 
beneficial  gastrointestinal  safety  profile  (Bombardier  et  al.  2000;  Silverstein  et  
al. 2000) and the negative cardiovascular profile have scrutinized (Bresalier et al. 
2005; Nussmeier et al. 2005; Solomon et al. 2005). Our study was not designed 
to detect such effects. 
The safety of the investigated drugs was evaluated in efficacy Studies I-II by 
regularly eliciting any adverse effects. The special interest was in nausea and 
vomiting, which were assumed to be reduced in the coxib treated groups. The 
only difference detected was in nausea score on the ward and in favour of 
etoricoxib. This concurs with the opioid sparing effect of etoricoxib. 
Surprisingly, there was no difference in the doses of antiemetics used. Römsing 
et  al.  also  failed  to  produce  clear  evidence  of  a  reduction  in  opioid  related  
adverse  events  after  reviewing  studies  on  the  opioid  sparing  effect  of  coxibs  
(Rømsing et al. 2005).The conclusion was also the same as the meta-analyses of 
all randomized trials comparing multimodal analgesia to morphine alone.(Elia et 
al. 2005)  
Study  III  was  designed  to  show any  renal  adverse  events  of  parecoxib  with  
sensitive markers. We were not able to find any clinical and only a few 
statistically significant differences between the placebo and the parecoxib group. 
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Oliguria was detected in both groups and could be explained by the laparoscopic 
surgery.  
COX-2 is expressed in the distal tubular component, macula densa, which 
damage can be detected by U-?GST. The statistically and clinically significant 
increase in U-?GST/U-crea ratio in both groups was two hours after the start of 
anaesthesia. The values normalized during the study period. The increase can be 
explained by the operation itself and indicates some distal tubular damage. There 
was no significant difference between the groups. There was a tendency to 
higher values in the control group than in the parecoxib-treated group. This 
underlines the safety of parecoxib, but further studies are warranted. 
 The preoperative level of the U-?GST/U-crea was relatively high in both our 
groups. One explanation is preoperative fasting, which causes relative 
dehydration. The values were lowest two hours after anaesthesia. This differs 
from the study showing an increase at that time point when comparing ketorolac 
to normal saline in patients undergoing breast surgery (Laisalmi et al. 2001). 
This  emphasizes  the  differences  in  the  action  sites  of  the  kidneys  between  the  
traditional NSAIDs and coxibs (Breyer et al. 2001). 
Cystatin  C  was  employed  as  a  sensitive  marker  of  GFR  (Harmoinen  et  al.  
2003; Shlipak et al. 2006). It has also been gradually introduced into clinical use 
(Sear 2005; Shlipak et al. 2006). Parecoxib was unable to increase the level of 
cystatin C. This means that GFR was not affected by parecoxib in our study.  
Efficacy studies on coxibs have reported sporadic renal adverse effects. 
Parecoxib 40mg administered every 12 hours for 36 hours after hip arthroplasty 
did not result in any significant increase in serum creatinine level (Malan et al. 
2003). Six out of 311 patients (0.003%) treated with valdecoxib twice a day after 
coronary surgery had increased serum creatinine level (over 180µmol/L or 
63µmol/L over baseline) (Ott et al. 2003). Reynolds et al. studied patients 
undergoing total knee replacement and reported one patient who developed acute 
renal failure after two doses of the study drug, valdecoxib 20mg. The patient’s 
baseline serum creatinine was increased (over 180µmol/L) and she was already 
oligouric in the postanaesthesia care unit prior to drug administration (Reynolds 
et al. 2003). Based on these three studies with seven cases reported Elia et al. 
concluded in their meta-analysis that the odds ratio for renal failure after major 
surgery was 4.86 (95%CI 1.01-23.4) if patients were treated with COX-2 
inhibitors and PCA morphine. The number needed to harm was 73 (95%CI 42-
277) (Elia et al. 2005). These numbers should be viewed with caution because of 
the limited data behind them. 
Koppert et al. were able to show a parecoxib-associated decrease in 
creatinine clearance postoperatively in elderly patients undergoing orthopaedic 
surgery. The decrease was clinically significant, 31.2%. Values were normalized 
after 4 hours although parecoxib treatment was continued for three days. 
Adequate recovery may be due to excessive fluid treatment. Mean central venous 
pressure was maintained over 13cmH2O during the operation (Koppert et al. 
2006). Another study on elderly persons receiving recommended doses of 
rofecoxib, indomethacin or placebo for six days showed a decrease in GFR if 
tested with the most sensitive test, inulin clearance. Creatinine clearance did not 
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change. The decrease in GFR was evident only if patients were on low salt diet 
but  vanished  on  normal  salt  diet  (Swan  et  al.  2000).  This  indicates  that  a  low  
sodium diet increases the dependency of renal function on prostaglandins. Low 
sodium diet induced state mimics contracted intravascular volume states like 
cardiovascular shock, cirrhosis and hypovolaemia. By contrast, rofecoxib used 
for seven days on elderly patients with moderate chronic renal failure had no 
effect  on  the  glomerular  filtration  rate  (Horackova  et  al.  2005)  The  number  of  
patients in this study was low, only ten, and the patients were also younger than 
in the studies by Koppert and Swan.  
There is increasing evidence of heterogeneities in COX-2 inhibitors 
(Hermann et al. 2005). Celecoxib has even shown a renoprotective effect in both 
animal (Hermann et al. 2005) and human studies (Pamuk and Cakir 2006). 
Selective COX-2 inhibitor called SC58236 is commonly used in laboratory 
animals and renoprotection has been demonstrated in several studies (Wang et al. 
2000; Cheng et al. 2002). Regularly administered rofecoxib reduced proteinuria 
in proteinuric patients (Vogt et al. 2009). Intrarenal administration of parecoxib 
in a porcine model was also able to attenuate an otherwise evident creatinine 
clearance decrease after cross-clamping of the suprarenal aorta (Hauser et al. 
2005). All these preliminary studies are still far from clinical use. 
The Cochrane Library has several times performed meta-analyses of the 
effects of nonsteroidal anti-inflammatory drugs on postoperative renal function 
in adults with normal renal function. The most recent version was edited in 2009 
but  the  conclusion  remained  the  same.  NSAIDs  caused  only  a  clinically  
unimportant transient reduction in renal function and should not be withheld 
from adults with normal preoperative renal function 
(http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD002765/frame.ht
ml). Use on risk patients should be regarded with caution. Elderly patients 
should be under supervision. This conclusion also applies to COX-2 inhibitors. 
3. Persistent postsurgical pain 
Pain is the main indication for knee arthroplasty and pain relief is the most 
important postoperative outcome. However, there are only few studies with 
persistent pain as the outcome measure after knee arthroplasty (Johnsson and 
Thorngren 1989; Burkart et al. 1993; Brander et al. 2003; Garcia et al. 2003; 
Harden et al. 2003; Nikolajsen et al. 2006). Most studies focus on the survival of 
the prosthesis.  
The prevalence of persistent pain in our study was significantly higher than in 
the majority of earlier studies. The study by Brander et al. reported 22.6% 
prevalence of significant pain (Visual Analog Scale>4) at three months, 18.4% at 
six months and 13.1% at one year (Brander et al. 2003). In another study the 
prevalence of moderate pain was ten percent (Garcia et al. 2003). Lundblad et al. 
reported prevalences close to those found in our study. The prevalence of 
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persistent pain was 24% at rest and 66% during movement at 18 months after 
surgery (Lundblad et al. 2008). 
The differences between the studies may be explained by the study methods. 
The pain of our patients was not assessed by clinicians as in some earlier studies 
(Brander et al. 2003; Garcia et al. 2003). The patients were able to express their 
feelings confidentially using the questionnaire, which may have increased the 
reported prevalence of pain. The inclusion criteria of pain intensity varied across 
studies. Mostly the patients in our study suffered from mild to moderate pain, but 
patients suffering from mild pain were excluded from the study by Brander et al. 
lowering the prevalence in their study (Brander et al. 2003). There were also 
remarkable differences between the time points for evaluating existing pain. The 
shortest time to the first evaluation was one month (Brander et al. 2003) and the 
latest time point was at seven years (Garcia et al. 2003). The recommended 
definition of postsurgical persistent pain allows us to call pain persistent if it has 
lasted more than two months (Macrae 2008). This is not reasonable in patients 
recovering from knee replacement. Pain after knee replacement seems to abate 
gradually. The time point for studying postsurgical pain should be long enough.  
Our strongest risk factor for persistent pain was the intensity of early (the 
first week) postoperative pain. Earlier studies on knee replacement have not 
included the intensity of early postoperative pain in their risk analyses, which has 
left  the  intensity  of  preoperative  pain  as  a  risk  factor  (Brander  et  al.  2003;  
Lundblad et al. 2008). Instead, the study on total hip arthroplasty revealed that 
persistent postoperative pain was related to the recalled intensity of early 
postoperative pain rather than to the intensity of preoperative pain (Nikolajsen et 
al. 2006).  
Female gender was a risk factor for persistent pain in our study as in many 
others (Brander et al. 2003; Rosseland and Stubhaug 2004; Kalliomäki et al. 
2008; Singh and Lewallen 2009). After hip arthroplasty the proportion of 
patients suffering from persistent pain was equal between women and men, but 
women were more likely to have daily or constant pain than men (Nikolajsen et 
al. 2006). 
Advanced age seems to reduce the risk of persistent pain after general 
surgery (Smith et al. 1999; Poobalan et al. 2001; Aasvang and Kehlet 2005; 
Poleshuck et al. 2006; Kalliomäki et al. 2008) . In our study age was not a linear 
risk factor for persistent pain, which concurs with other orthopaedic studies 
(Brander et al. 2003; Lundblad et al. 2008). In the study by Singh et al. younger 
patients (61-70 years) even had reduced risk of persistent pain after revision hip 
arthroplasty (Singh and Lewallen 2009). 
Other factors associated with increased postsurgical persistent pain are anxiety 
and depression (Tasmuth et al. 1996; Tasmuth et al. 1996; Brander et al. 2003; 
Rolfson et al. 2009; Singh and Lewallen 2009), but our questionnaire was not 
designed to identify depression or anxiety.  
The hypothesis of this study was that the larger the tissue injury (bilateral vs. 
unilateral arthroplasty group), the higher the prevalence of persistent pain. 
Surprisingly  there  was  no  association  in  this  respect.  These  results  are  in  line  
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with those of an earlier study (Powell et al. 2006) and support the consensus on 
offering bilateral knee arthroplasty when needed. 
4. Strengths and weaknesses of the studies 
Both dose efficacy studies (I-II) were equally well designed: prospective, 
randomized, double-blinded and placebo controlled. The sample size was based 
on calculations to enroll an ideal number of patients in the studies.  
The  weaknesses  were  in  Studies  III  and  IV.  The  major  limitation  of  Study  III  
was small sample size with wide variation in the data. This increases the risk of 
type II error. We had assumed that our physiological stressful study setting 
would have increased the sensitive renal marker values even in this small study 
population. Awareness of wide data variation in a clinical setting provides 
valuable information for other researchers. 
The major limitations in Study IV were the relatively low response rate (65.7%) 
and the variable time period from surgery to the questionnaire. Psychosocial 
factors were likewise not included in the questionnaire. The response rate was 
considered sufficient to draw conclusions from the results, but a higher response 
rate might have been obtained with several reminders. This would have 
increased the power of the results. Fortunately, the original size of study sample 
(855 patients) is much larger than in earlier prevalence studies (Brander et al. 
2003; Garcia et al. 2003; Lundblad et al. 2008). 
The time interval from surgery to the questionnaire varied from four to 22 
months. The minimum duration for persistent pain is two months (Macrae 2008). 
This requirement was met in our study. However, the long time interval for some 
responders may have affected the memory of acute postoperative pain. This was 
well illustrated in the study, where the women who had chronic pain after breast 
cancer surgery remembered having had more severe postoperative pain than 
those women who had no chronic pain (Tasmuth et al. 1996). Preoperative pain 
scores were not influenced by memory because they were taken from the 
hospital registry. Moreover, a long interval usually increases the likelihood of 
false negatives (Poobalan et al. 2001) or in other words increases the likelihood 
of true positives (Dworkin et al. 2010). This in turn underlies the significance of 
the high prevalence of persistent pain found in our study. A fixed time interval 
between surgery and the questionnaire would have improved the quality of this 
study. 
5. Challenges in studying postsurgical pain 
Pain is always a subjective experience, which makes it difficult to assess 
(Merskey 1994). Pain assessment method should be valid and comparable. 
Visual analogue scale (VAS) and numeral rating scale (NRS) are the most 
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reliable methods (Breivik et al. 2008), but still useless in some patient groups 
such as infants or older adults with dementia (Karp et al. 2008). 
Pain is also culturally dependent, which means that the results from one study 
cannot be directly applied to some other population. The same problem occurs 
with different genders and races (Kalso et al. 2009). 
Pain has many components which should be evaluated separately. Several 
pharmacotherapeutic studies have reported only spontaneous pain relief, 
although pain relief in movement might be even more important in regarding the 
patient’s rehabilitation (Breivik et al. 2008). 
The efficacy of pain medication seems to also vary between surgical 
procedures (Rømsing and Møiniche 2004) suggesting different components of 
pain: incisional, visceral, bone related, neuropathic etc. Efficacy differences also 
arise from different time intervals between the investigated drugs used (Dworkin 
et al. 2010). Pharmacodynamic and pharmacokinetic profiles should be noted in 
advance. 
The assessment of baseline pain is essential in analgesic efficacy studies 
(Breivik et al. 2008) making the evaluation of pre-emptive analgesia demanding. 
The aetiology of persistent postsurgical pain is always multifactorial (Kehlet 
et al. 2006b; Macrae 2008). Reliable risk analysis of persistent pain needs a wide 
perspective to include all possible risk factors in the model tested. The more risk 
factors are included, the more patients must be enrolled. 
Challenges in studying pain are faced by different pain organizations, which 
have led to detailed recommendations about the study designs to be followed 
(Dworkin et al. 2010). This means that studies in the future should be more 
reliable and easier to compare against each other. 
6. Future aspects 
The efficacy of COX-2 inhibitors has been proven in several studies and meta-
analyses (Gilron et al. 2003; Rømsing and Møiniche 2004; Elia et al. 2005). A 
cardiovascular risk profile is also well established (Bresalier et al. 2005; 
Nussmeier et al. 2005; Solomon et al. 2005). Future studies should concentrate 
on other adverse effects of COX-2 inhibitors. There is some controversy on the 
both renal effects (Hermann et al. 2005) and the bone healing (Beck et al. 2005; 
Vuolteenaho et al. 2008; Boursinos et al. 2009), which should be investigated. In 
addition, the positive role of coxibs in the inhibition of carcinogenesis (Rostom 
et al. 2007) could be studied in a perioperative model. An ideal coxib is still 
lacking in clinical practice. 
Assessment of risk factors for persistent postsurgical pain is essential in the 
future, too (Macrae 2008). Risk factors identified might open a curative window 
to persistent pain. Most efforts will also be invested in solving genetic 
susceptibility (Stamer and Stuber 2007b). The patient at elevated risk of 
persistent pain should in turn be optimally treated. The optimal combination of 
medications needs to be solved for these patients (Dworkin et al. 2010).  
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Conclusions 
Based on these studies the following conclusions can be drawn: 
 
1. Neither the recommended dose of parecoxib, 40mg nor the double dose 
80mg, reduced the fentanyl consumption during early postoperative 
period after laparoscopic cholecystectomy. 
 
2. The recommended dose of etoricoxib, 120mg given in premedication, is 
effective for the treatment of pain during the early postoperative period 
after laparoscopic cholecystectomy. Combining paracetamol 1000mg 
with etoricoxib 120mg had no additional effect. 
 
3. A  single  dose  of  80mg  parecoxib  was  well  tolerated  by  the  kidneys  
during the next 20 postoperative hours in patients undergoing 
laparoscopic hysterectomy with ASA physiological status I-II and age 
under 60 years. 
 
4. The type of surgery in knee arthroplasty did not correlate with the 
prevalence of persistent pain. Persistent pain after knee arthroplasty 
seems to be a far more frequent problem than assumed. The preoperative 
duration of pain and the intensity of early postoperative pain are the risk 
factors to be addressed in prevention of postsurgical persistent pain. 
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Appendix 
The questionnaire of Study IV 
Background:  
 
1. Weight________kg 
2. Height________cm 
 
Pre/Post-surgical status 
 
3. How long did you suffer from pain in the operated knee before 
surgery?________months 
4. How much did this pain disturb your daily life? 
1 not at all 
2 a little 
3 to some extent 
4 a lot 
5. How long did you have pain after surgery?______weeks/months 
6. How would you describe the pain during the first week after the 
operation? 
1 mild 
2 moderate 
3 severe 
4 unbearable 
 
At present 
 
7. Do you still have pain in your operated knee? 
1 yes, go to Question 9 
2 no (no further questions) 
8. Do you have pain at rest? 
1 yes 
2 no 
9. How would you describe the degree of pain at rest? 
1 mild 
2 moderate 
3 severe 
4 unbearable 
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10. Do you have pain during exercise? 
1 yes  
2 no, go to Question 12 
11. How would you describe the degree of pain during exercise? 
 1 mild 
 2 moderate 
3 severe 
4 unbearable 
12. How much does this pain disturb your daily life? 
1 not at all 
2 a little 
3 to some extent 
4 a lot 
13. How much does this pain disturb your sleep? 
1 not at all 
2 a little 
3 to some extent 
4 a lot 
14. Do you still use any medicine against postsurgical knee pain? 
Which?______ 
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Lack of analgesic effect of parecoxib following
laparoscopic cholecystectomy
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Background: The cyclo-oxygenase-2 inhibitor, parecoxib, can be
administered parenterally. The recommended dose for post-
operative use is 40 mg twice daily, which may not be the appro-
priate dose for the treatment of visceral pain. We studied the effect
of a single dose of parecoxib of either 40 or 80 mg in laparoscopic
cholecystectomy, and its effect on opioid-induced side-effects.
Methods: Seventy-three patients scheduled for elective laparo-
scopic cholecystectomy were enrolled in this prospective, random-
ized, double-blind study. Patients were randomized into three
groups: a placebo-treated control group, a 40-mg parecoxib-treated
group (P40) and an 80-mg parecoxib-treated group (P80). We
recorded the cumulative fentanyl consumption during the first
20 h post-operatively by patient-controlled analgesia equipment,
the pain scores during rest, coughing and mobilization (visual
analogue scale, 0–10), the worst pain during the first 2 h post-
operatively and in the following 18 h, and the side-effects by
questionnaire.
Results: No significant differences in fentanyl consumption
between the three groups could be detected. The worst pain
experienced between 2 and 20 h post-operatively on the wardwas
significantly lower in the P80 group than in the control group.
Conclusion: The recommended dose of parecoxib, 40 mg, is not
effective for the treatment of pain during the early post-operative
period after laparoscopic cholecystectomy. Doubling the dose to
80 mg seems to improve the results.
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OPIOIDS are commonly used for post-operativepain treatment, although their side-effects are
well known. Non-steroidal anti-inflammatory drugs
(NSAIDs), used for post-operative pain, are valuable
because they reduce the use of opioids by about 20–
50% depending on the pain model employed (1–3).
Because cyclo-oxygenase-2 (COX-2) inhibitors are
not associated with the various side-effects of tradi-
tional NSAIDs, such as peptic irritation and, in
particular, interference with haemostasis (1–3), they
can be used more often for pain treatment during the
peri-operative period. However, renal side-effects are
similar (1–3). The risk for cardiovascular events may
be increased when COX-2 inhibitors are used (4, 5).
Parecoxib is a COX-2 inhibitor which can be
administered parenterally. It is a pro-drug metabo-
lized by the liver to valdecoxib. The analgesic effect
of valdecoxib starts at 10 min, but the maximum
effect (tmax) is seen between 2 and 4 h. The t1/2 of
valdecoxib is 6–10 h (1). Its peri-operative use has
been studied in dental (6, 7), orthopaedic (8, 9),
gynaecological (10–13) and coronary artery bypass
(14) surgery, reducing the need for additional pain
treatment with opioids by 20–40%. The peri-opera-
tive use of parecoxib improved the quality of patient
recovery following laparoscopic cholecystectomy
(15–17). The dose of parecoxib effective for post-
operative pain relief varies from 20 to 80 mg depend-
ing on the type of surgery. The recommended dose
for peri-operative use is 40 mg twice daily.
Visceral pain is more therapy resistant than pain
following orthopaedic or dental surgery, for example
(18). In addition, the results of previous studies on the
effect of parecoxib on post-operative pain relief fol-
lowing surgery of the viscera, published so far, have
been biased by the fact that the statistical analyses of
the results have been performed in a manner not
adhering to the rules of statistical assumptions. Mostly,
only parametric analyses have been employed in the
measurements, although a non-normal distribution of
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the outcome variables, such as patient behaviour
during pain and the cumulative consumption of
analgesics, is well known (19, 20). We therefore
decided to study the effect of a single dose of parecoxib
of either 40 or 80 mg on post-operative pain, and its
possible influence on opioid-induced side-effects, such
as nausea, in patients undergoing laparoscopic chole-
cystectomy. Pain after laparoscopic cholecystectomy
has incisional, visceral and shoulder pain components
(21). The hypothesis was that parecoxib 80 mg would
be a more appropriate dose than 40 mg in this mixed
pain model. The primary end point was the reduced
cumulative consumption of analgesics during the first
20 h post-operatively. We gave parecoxib at the end of
surgery because it has been judged to perform better
when given as treatment than as prophylaxis (22).
Materials and methods
The study was approved by the ethics committees of
the participating institutions (District Hospitals of
Valkeakoski and Vammala, Finland) and the Finnish
National Medical Board. Written informed consent
was obtained from each patient. Seventy-three pa-
tients scheduled for elective laparoscopic cholecys-
tectomy were enrolled in this prospective,
randomized, double-blind study. The inclusion crite-
ria were as follows: age between 30 and 60 years;
ASA physiological status I–II; weight between 60 and
100 kg. The exclusion criteria included allergy to
aspirin-like drugs or sulphonamide, bronchial
asthma, liver or renal disturbances, peptic ulcer,
bleeding disorder, pregnancy, substance abuse and
chronic pain.
Patients were randomized into three groups: pla-
cebo-treated control group (placebo group), 40-mg
parecoxib-treated group (P40 group) and 80-mg
parecoxib-treated group (P80 group). The randomi-
zation procedure involved computer-generated ran-
dom numbers in opaque envelopes. The study
medication was given at the end of anaesthesia. All
solutions were colourless in a volume of 4 ml and
were prepared by a staff nurse not involved in the
study.
Pre-medication was oxazepam (15 mg) in all
groups. Anaesthesia was standardized. Induction
was with fentanyl (2 mg/kg), propofol (2 mg/kg)
and rocuronium (0.6 mg/kg). An equal amount of
fentanyl was given about 3 min before skin incision
for trocars. All operations were performed by expe-
rienced laparoscopic surgeons using the standard
technique with two 12-mm trocars and two 5-mm
trocars. Warm (37 8C) CO2 insufflation was used and
the intra-abdominal pressure was kept at 12 mmHg.
Anaesthesia was maintained with sevoflurane 2–3%
in air–O2 (66% : 34%). Muscle relaxation was main-
tained between train-of-four (TOF) 0/4–2/4 with
rocuronium. EtCO2 was maintained between 5.0
and 5.5% by adjusting the ventilation. Residual
neuromuscular block was antagonized with neostig-
mine and glycopyrrolate. The wounds were not
infiltrated with local anaesthetics.
All patients were instructed pre-operatively and
assisted post-operatively in the use of the patient-
controlled analgesia (PCA) device, programmed to
deliver 50 mg of fentanyl over 2 min. The lockout time
was 5 min, and the maximum dose was 10 ml/h
( ¼ 500 mg) during the first 2 h in the recovery room
and 5 ml/h ( ¼ 250 mg) on the ward until 20 h after
the end of surgery. During emergence from anaes-
thesia, the recovery room nurses were allowed to
give additional fentanyl boluses via the PCA device
on request of the patients.
During the pre-anaesthetic round, the patients
were instructed in the use of a visual analogue scale
(VAS, 0–10). Pain intensity at rest, during coughing
and during leg elevation was assessed using VAS at
the pre-operative round, on arrival in the operating
theatre, and at 1, 2, 4, 6, 8, 10 and 20 h after the end of
surgery (0, no pain at all; 10, unbearable pain). The
patients were asked to evaluate the worst pain score
at rest encountered during the previous period at 2
and 20 h after the end of surgery. The times from the
end of surgery until the first bolus of fentanyl
delivered by the PCA device and the times to eye
opening and head raising on demand were recorded.
The need for additional pain treatment was evalu-
ated by the frequency and amount of fentanyl
boluses during the first 20 h post-operatively.
The patients were asked about nausea using VAS
during the pre-operative round, on arrival at the
operating theatre, and at 1, 2, 4, 6, 8, 10 and 20-h post-
operatively (0, not at all; 10, worst imaginable). At the
same time points, the patients were also asked about
the type and degree (VAS) of other possible side-
effects of any kind. The anti-emetics used were
recorded at 2 and 20 h post-operatively. At the end
of the observation period, the patients were asked to
express their opinion concerning the efficacy of the
pain-relieving treatment (0, excellent; 1, good; 2,
unknown; 3, fair; 4, poor).
The sample size estimation was based on our
hypothesis that parecoxib would reduce the need
for post-operative pain treatment during the first 20 h
post-operatively to the same degree as traditional
NSAIDs (18, 23). We calculated that, with 20 patients
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per group, the sample size would be sufficient to
detect a difference of 40% in the overall amount of
fentanyl boluses during the first 20 h post-opera-
tively between the P80 and control groups (a ¼ 0.05,
power ¼ 80%).
The cumulative fentanyl doses and VAS score
variables for pain measurements and fatigue were
treated as continuous. Most were non-normally dis-
tributed and medians and quartiles are reported. The
significance test between the study groups was the
Kruskall–Wallis test. Normally distributed data was
reported by means and tested by analysis of variance
(ANOVA) (post hoc least-significant difference). Cate-
gorized variables are presented as percentage fre-
quencies, with w2 tests as the significance test. P <
0.05 was considered to be statistically significant. The
analysis was performed using SPSS for Windows,
version 11.5.
Results
Seventy-three patients consented to participate in the
study. Of these, nine were excluded for the following
reasons: the laparoscopic operation was changed to
open cholecystectomy in four patients; local anaes-
thetics were used in one patient; one non-Finnish-
speaking patient was unable to answer the questions;
two patients were rejected because of violations of
the protocol (weight of more than 100 kg); one
patient was rejected because of an extremely difficult
and time-consuming operation (more than 120 min).
Of the remaining 64 patients, there were no signifi-
cant differences between the treatment groups with
regard to age, weight, gender, ASA risk qualification
and the duration of the operation (Table 1).
The cumulative consumption of fentanyl, ex-
pressed as medians and quartiles, is shown in
Table 2. There was a tendency to use less fentanyl
in the P40 and P80 groups compared with the
placebo group throughout the entire post-operative
study period from 1 to 20 h post-operatively. The
difference was not statistically or clinically signifi-
cant. PCA demands were almost equal to delivered
doses in all groups (correlation, 0.9).
There were no significant differences between the
groups with regard to pain scores at rest or during
coughing and leg elevation at any time point
(Table 3). The worst pain on the ward, evaluated by
VAS and expressed by means and standard devia-
tions, was significantly lower in the P80 group (3.9 
1.9) than in the placebo group (5.8  3.0) (P ¼ 0.014).
In the global evaluation of the quality of post-
operative analgesia, patients rated it from good to
excellent in each group, but there were two patients
in the placebo group who evaluated their analgesia
as fair or poor (Table 4). Four patients did not answer
the question about the quality of analgesia.
There was no clinically or statistically significant
difference between the groups with regard to post-
operative nausea when evaluating nausea by VAS or
comparing the anti-emetic doses used.
The frequency of other side-effects was rare and of
a slight to moderate degree. Three patients in each
group complained of slight to moderate headache
(VAS < 5) and one patient in each group suffered
from dizziness (VAS  6). Blurred vision (VAS  2)
was experienced by one patient in the placebo group
and one in the P80 group.
Discussion
In this study in patients undergoing elective laparo-
scopic cholecystectomy, we demonstrated that there
was no significant difference in the cumulative
fentanyl consumption during the first 20 h post-
operatively in the 40- or 80-mg parecoxib-treated
groups compared with the placebo group.
The original studies evaluating the recommended
dose of parecoxib were mostly performed in patients
undergoing minor surgery, e.g. dental or orthopaedic
surgery (6–9). Clinical studies on orthopaedic pa-
tients have managed to reduce opioid consumption
by 40% (8, 9). Pain after laparoscopic cholecystec-
tomy is intense if local anaesthesia is not employed:
the degree of pain until the first post-operative
morning has been shown to be strong or even
unbearable in about half of patients (24). Pain after
laparoscopic cholecystectomy has several compo-
nents (incisional, visceral and shoulder pain) and
pain intensity varies between patients (21). In addi-
tion, visceral pain seems to be more resistant to the
Table 1
Baseline characteristics of the three study groups (mean  SD or
range).
Placebo P40 P80
n ¼ 20 n ¼ 23 n ¼ 21
Age (years) 41  10 45  9 44  12
Weight (kg) 75  11 77  14 77  12
ASA I/II 12/8 11/12 13/8
Sex (male/female) 6/14 6/17 4/17
Duration of
surgery (min)
54 (19–106) 63 (10–150) 56 (19–103)
P40, parecoxib 40 mg; P80, parecoxib 80 mg.
No significant differences between the groups.
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analgesic effect of NSAIDs (18). Therefore, the rec-
ommended dose cannot be regarded as similar in
a visceral pain model as in orthopaedic or dental pain
models.
In contrast with other published studies on mixed
pain (10–12, 15–17), parecoxib, 40 mg, failed to
demonstrate any analgesic effect in our study. Some
of the previous studies have used parametric tests,
although the normality of the data was not clear (10,
12). The duration of our study was 20 h post-
operatively; however, the evaluation of only the first
20 h may not be the appropriate end point to
determine the efficacy of coxibs. Some studies have
demonstrated that the analgesic efficacy of parecoxib
increases during the study period (15). One study
demonstrated the efficacy of parecoxib in relieving
acute post-operative pain following gynaecological
laparotomy, but the study started on the first post-
operative day (11). This phenomenon may be ex-
plained by the fact that NSAIDs work better when
pain is less intense (25). Alexander (26) concluded in
his review that NSAIDs are ineffective for shoulder
pain, commonly seen after laparoscopy. We did not
investigate shoulder pain separately.
The relatively small number of patients may also
explain some of the discrepancies with other studies.
In our power analysis, we calculated the sample size
to be 20 patients per group to demonstrate a 40%
decrease in cumulative opioid consumption,
a decrease we believe to be clinically meaningful
when treating moderate pain. A statistically signifi-
cant difference may have been reached by gathering
more data, but this would not have resulted in
a significant clinical difference (20%).
We chose to give only a single dose of parecoxib,
because the maximum daily dose recommended by
the drug company is 80 mg. The drug companies also
advise that valdecoxib be prescribed on a once-daily
basis. The t1/2 of parecoxib (c. 8 h) should be
sufficiently long to secure sufficiently high plasma
levels during the first 20 h following administration.
The maximum effect of parecoxib was seen 6–8 h
post-operatively, which matches the pharmacokinet-
ics of parecoxib.
The opioid-sparing effect of a coxib is most bene-
ficial when it also results in a decrease in post-
operative side-effects (27, 28). Our study was not
powered for side-effects, but the reported opioid-
related side-effects did not differ between the groups.
This has also been found in lower abdominal and
orthopaedic pain models (8–10). Gan et al. (17)
Table 2
Cumulative post-operative fentanyl consumption during the study [median (Q1, Q3)].
Group 1 h 2 h 4 h 6 h 8 h 10 h 20 h
Placebo 2 (1, 3) 4 (2.5, 5.5) 5 (4, 11) 6 (4, 12.5) 7 (5, 14.5) 8 (5, 15) 10 (6, 22)
P40 2 (1, 3.5) 3 (2, 4.75) 5 (3, 7.75) 5 (3.25, 10.75) 5.5 (4, 11) 6 (5, 12.75) 8 (6, 16.75)
P80 1 (1, 2) 2 (1, 4.75) 4 (2, 5.75) 4 (2.25, 7) 5.5 (4.25, 8) 6.5 (4.25, 8) 8.5 (5.5, 11.75)
P40, parecoxib 40 mg; P80, parecoxib 80 mg.
No significant differences between the groups (Kruskall–Wallis test).
Table 3
Medians of the pain scores (visual analogue scale, 0–10) at rest,
during coughing and during leg elevation.
1 h 2 h 4 h 6 h 8 h 10 h 20 h
At rest
Placebo 4.5 3.3 2.0 2.0 1.0 1.0 1.0
P40 4.0 3.0 2.0 1.0 1.0 1.0 1.0
P80 4.0 2.0 2.0 1.5 1.5 1.0 1.0
Coughing
Placebo 6.0 5.0 4.0 3.0 3.0 3.0 2.0
P40 5.0 4.0 4.0 3.0 3.0 2.0 3.0
P80 4.0 4.0 3.0 2.8 3.0 2.0 2.0
Leg elevation
Placebo 5.0 4.3 4.0 3.0 2.5 2.0 2.5
P40 5.0 4.0 3.0 3.0 3.0 2.0 3.0
P80 5.0 4.0 3.0 2.5 2.0 2.0 2.0
P40, parecoxib 40 mg; P80, parecoxib 80 mg.
No significant differences between the groups (Kruskall–Wallis
test).
Table 4
Global evaluation of analgesia (n).
Placebo P40 P80
n ¼ 17 n ¼ 22 n ¼ 21
Excellent 9 17 14
Good 6 5 7
Unknown 1 0 0
Fair 1 0 0
Poor 1 0 0
P40, parecoxib 40 mg; P80, parecoxib 80 mg.
No significant differences.
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showed a decrease in opioid-related side-effects in
patients recovering from laparoscopic cholecystec-
tomy and receiving parecoxib pre-operatively and
valdecoxib post-operatively. They used the opioid-
related Symptoms Distress Scale questionnaire every
24 h for 7 days, accumulating data from each
individual, not spontaneous complaints as in our
and most other studies.
Publications on the effect of analgesics should
include information about the normality of the data
to provide the reader with more accurate information
on the statistical analysis of the study results. Nor-
mality should be tested at least by histogram (19, 20),
and parametric tests should be used only if the
results are normally distributed. Parametric tests in
non-normally distributed data may be misleading.
They may find a statistical difference when there is
none. However, in the published literature, para-
metric tests are often used to compare opioid con-
sumption (8, 9, 17), although normality is not
demonstrated.
We conclude that the recommended dose of par-
ecoxib (40 mg) during the early post-operative period
is not effective for laparoscopic cholecystectomy.
Doubling the dose to 80 mg seems to improve the
results.
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Etoricoxib pre-medication for post-operative pain after
laparoscopic cholecystectomy
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Background: Etoricoxib alleviates and prevents acute pain. The
hypothesis of our study was that the pre-operative use of
etoricoxib would reduce the post-operative need for additional
pain treatment.
Methods: In this double-blind, randomized and active placebo-
controlled study, 75 patients were pre-medicated 1.5 h before
elective laparoscopic cholecystectomy with 120 mg of etoricoxib
(E120 group), the same dose of etoricoxib combined with 1 g of
paracetamol (E þ P group) or placebo (Pla group). To alleviate
post-operative pain, a patient-controlled analgesia (PCA) device
was programmed to deliver 50 mg of fentanyl intravenously
(lockout time, 5 min). The pain intensity and nausea were
assessed using a visual analogue scale (VAS). The number of
patients with post-operative nausea and vomiting was recorded.
Blood loss was compared between the groups. Because the
operations are almost blood-less, the operation time was also
recorded to compare the possible effect on bleeding time.
Results: Pre-medication with etoricoxib or etoricoxib plus para-
cetamol had a statistically significant fentanyl-sparing effect
2–20 h post-operatively compared with placebo (P ¼ 0.001).
No significant differences were demonstrated in fentanyl-sparing
effect between the E120 and E þ P groups. No significant
differences in pain intensity were found between the three study
groups. No significant differences were observed between the
groups with regard to nausea, blood loss, duration of anaesthesia
or duration of surgery.
Conclusion: Etoricoxib is suitable for pre-medication before
laparoscopic cholecystectomy as it reduces the need for post-
operative opioids. Opioid-related side-effects, however, were not
reduced in the present study, despite the observed opioid-sparing
effect of etoricoxib and combined etoricoxib and paracetamol.
Accepted for publication 5 March 2006
Key words: clinical trial; cumulative fentanyl; etoricoxib;
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NON-STEROIDAL anti- inflammatory drugs(NSAIDs) are effective analgesics for the con-
trol of moderate post-operative pain (1). The combi-
nation of opioids with, for example, NSAIDs reduces
the dose of opioid needed to achieve pain relief (2),
and may reduce the incidence of side-effects, either
by reducing the need for opioids or by improving
pain relief (3).
The inhibition of cyclo-oxygenase (COX) is the
principal mechanism for both the efficacy and
toxicity of NSAIDs (4), and it has been demon-
strated that COX exists as at least two isoenzymes:
COX-1 and COX-2 (5). The major reason for the
development of specific COX-2 inhibitors was the
maintenance of the anti-inflammatory and analge-
sic effects without altering the homeostatic func-
tions of COX-1.
Although opioids are suitable for intense post-
operative pain, they have common side-effects, such
as post-operative nausea and vomiting (PONV) and
fatigue. These unpleasant side-effects may be
avoided by reducing the need for opioids by
combining NSAIDs and opioids. Reports on the
analgesic efficacy and adverse effects of different
COX-2 inhibitors for acute post-operative pain have
been the subject of recent systematic reviews (6–9).
However, the data did not support the common
opinion that opioid sparing with COX-2 inhibitors
provides a clinical beneficial effect with respect to
opioid-related adverse events.
Etoricoxib is effective in low back pain, osteoar-
thritis, rheumatoid arthritis, acute gout and primary
dysmenorrhoea (10), but etoricoxib pre-medication
before surgical operations has not been studied in
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detail. The duration of action of etoricoxib is suffi-
ciently long to enable dosing once a day. After the
oral administration of etoricoxib, the maximum
serum concentration is achieved in 1 h and the
bioavailability is almost 100%. The half-life (T1/2) of
etoricoxib is 22 h (11).
Paracetamol is commonly used for the manage-
ment of peri-operative pain. In the studies reviewed,
paracetamol seems to have almost equal efficacy to
NSAIDs, but there is no clear evidence as to whether
the combination of paracetamol and NSAIDs is
beneficial.
Because etoricoxib seems to alleviate and prevent
acute pain and may reduce post-operative pain more
generally, we planned the following active placebo-
controlled, double-blind, randomized study in
patients undergoing elective laparoscopic cholecys-
tectomy. The aim of this study was to test the
analgesic efficacy of etoricoxib pre-medication for
post-operative pain relief. In addition, we examined
pre-medication with a combination of paracetamol
and etoricoxib.
The primary endpoint was as follows: (i) does pre-
operative etoricoxib reduce the post-operative need
for additional pain treatment in patients undergoing
elective laparoscopic cholecystectomy under general
anaesthesia (i.e. the post-operative opioid-sparing
effect of etoricoxib in humans). The secondary end-
points were as follows: (ii) does the addition of para-
cetamol to etoricoxib improve the analgesic effect of
the pre-medication; (iii) does the pre-medication have
an impact on PONVor fatigue; and (iv) does the pre-
medication influence the operation time and/or blood
loss during surgery.
Materials and methods
The study was approved by the ethics committees of
the participating institutions (University Hospital of
Tampere, District Hospital of Valkeakoski) and the
Finnish National Medical Board. Written informed
consent was obtained from each patient. The inclu-
sion criteria were as follows: age of 16–70 years; ASA
physiological status of I–III (physiological status
score of the American Society of Anesthesiologists);
patient scheduled for elective laparoscopic cholecys-
tectomy. The exclusion criteria were as follows:
allergy to NSAIDs; chronic pain syndrome; psychi-
atric disorder; substance abuse; gastrointestinal
bleeding; any disease of the liver or the kidneys;
pregnancy; congestive heart disease; angina pectoris;
cerebrovascular circulatory symptoms; body mass
index (BMI) over 40. Our intention was to include
overweight patients in the study in order to represent
the Finnish cholecystectomy population in the
results.
All patients were operated on at Valkeakoski
District Hospital. The patients were divided into
three groups using a random number table. A nurse
from a department not involved in the study pre-
pared the drug-containing bags, each containing four
tablets according to the list. In the E120 group, the
bag contained one 120-mg tablet of etoricoxib, one
15-mg tablet of oxazepam and two placebo tablets; in
the Eþ P group, the bag contained one 120-mg tablet
of etoricoxib, two 500-mg tablets of paracetamol and
one 15-mg tablet of oxazepam; in the Pla group, the
bag contained three placebo tablets and one 15-mg
tablet of oxazepam. We used a very small dose of
oxazepam in all groups as sedative pre-medication
and as an active placebo in the Pla group. The
medication was given to the patients about 1.5 h
before the induction of anaesthesia.
The name of the study and the running number of
the patient were stated on the bags. For safety
reasons, the randomization list, including the con-
tents of the study bag of each patient, was kept in the
recovery room.
Anaesthesia was induced with 2 mg/kg of fentanyl
adjusted to the nearest 25 mg/kg, followed by 2–3
mg/kg of propofol. The same dose of fentanyl was
given again 4 min before incision. After induction, one
dose of 15mg/kg of dehydrobenzperidole was admin-
istered as a prophylactic anti-emetic agent. Anaesthe-
sia was further maintained with sevoflurane in 66%
air in O2. During the maintenance of anaesthesia, the
sevoflurane concentration was adjusted to keep the
systolic blood pressure between 85 and 130 mmHg.
Neuromuscular blockade was kept at the level of T1
0–15% and the block was antagonized with glycopyr-
rolate combined with glycostigmine. Mechanical ven-
tilation was adjusted to keep the end-tidal CO2
between 5 and 5.5%. The sizes of the four troacars
were: 12 mm, 10 mm and 2  5 mm. The pressure of
CO2 insufflation was kept under 12 cmH2O. At the
end of the operation, the four incisions were infiltrated
with 20 ml of 5 mg/ml of bupivacaine with epineph-
rine by the surgeon. The durations of anaesthesia and
operation were recorded. The weight of blood loss
was measured and adjusted to the nearest 5 ml. One
litre of Ringer’s acetate was infused intra-operatively,
a second one during the first six post-operative hours,
and 1 l of 0.3 M sodium chloride in 5% glucose during
the next 12 h.
Monitoring during anaesthesia comprised continu-
ous electrocardiogram and heart rate, pulse oximetry,
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non-invasive arterial pressure, measurement of the
end-tidal CO2 and measurement of the expiratory
end-tidal sevoflurane concentration. All of these
parameters were recorded at 5-min intervals.
All patients were instructed pre-operatively and
assisted post-operatively to use a patient-controlled
analgesia (PCA) device, programmed to deliver 50
mg of fentanyl during 1 min. The lockout time was 5
min, and the maximum dose was 500 mg/h during
the first 2 h in the recovery room and 250 mg/h on the
ward until 20 h after the end of surgery. During
emergence from anaesthesia, the recovery room
nurses were allowed to give additional fentanyl
boluses via the PCA device on request of the patients.
During the pre-anaesthetic round, the patients
were also instructed in the use of a visual analogue
scale (VAS; 0–10: 0, no pain at all; 10, unbearable
pain). Pain intensity at rest, during coughing and
during leg elevation were assessed using VAS at the
pre-operative round, on arrival in the operating
theatre, and at 1, 2, 4, 10 and 20 h after the end of
surgery. The patients were asked to evaluate the
worst pain score at rest encountered during the
previous period at 2 h and at 20 h after the end of
surgery. The need for additional pain treatment was
evaluated by the frequency and amount of fentanyl
boluses during the first 20 post-operative hours. At
the end of the observation period, the patients were
asked to express their opinion concerning the efficacy
of the pain-relieving treatment on a 1–5 satisfaction
scale (1, very satisfied; 5, very unsatisfied).
The patients were also asked about fatigue and
nausea using VAS during the pre-operative round, on
arrival in the operating theatre, and at 1, 2, 4, 10 and
20 h post-operatively (0, none at all; 10, worst
imaginable). On arrival in the operating theatre, as
well as at 4 and 20 h post-operatively, the patients
who had vomited or suffered from nausea during the
previous period were recorded, together with any
use of anti-emetic medication.
Statistical methods
The sample size estimation was based on the
assumption that etoricoxib would reduce the need
for opioids by 33% as doNSAIDs (12). Thus, with a¼
0.05 and power ¼ 80%, the sample size was 23
patients in each group.
Demographic and other background data are
presented as frequencies, means and standard devia-
tions (SD). Measures of PONV, having only a few
non-zero values, were dichotomized according to the
presence of PONV, and are presented as percentage
frequencies For single variables, including time
point-specific ones, the significance tests between
the study groups included chi-squared, one-way
analysis of variance and independent sample t-test,
as appropriate. The PONV score includes nausea and/
or vomiting. Retching was not recorded separately.
The original VAS values (0–100) were divided by
10 and rounded to the nearest integer. Factors
measured before or during the operation had non-
normal distributions and were therefore reported as
medians and quartiles; the significance test for group
differences was the Kruskall–Wallis or Mann–
Whitney test, as appropriate. The non-normality of
the repeatedly measured post-operative cumulative
fentanyl doses, as well as the pain and fatigue
measurements, was corrected by applying a square-
root transformation. The differences in these trans-
formed variables between the study groups over time
could then be examined by repeated measures anal-
ysis of variance with the least significant difference
multiple comparisons test. The reported descriptives
of the results were, however, re-transformed by
squaring. P values of less than 0.05 were considered
to be statistically significant. Except in the repeated
measures analysis of variance, Bonferroni correction
was not considered to be appropriate. The analysis
was performed with SPSS for Windows, version 11.5.
Results
Seventy-five patients consented to participate in the
study over 13 months. Two patients in the Pla group
needed open cholecystectomy and were excluded
from the data. In addition, one operation in the E120
group was cancelled as a result of severe macro-
scopic hepatic cirrhosis, which was diagnosed at the
start of laparoscopy. Apart from these three patients,
the evaluation of the pre-operative status and the
need for PCA fentanyl was performed in all other
patients (n ¼ 72). VAS scores for post-operative pain
and PONV were analysed only for 66 patients,
because some of the data sheets were incompletely
filled during the night time period.
There were no statistically significant differences
between the groups with regard to age, sex, weight,
height and ASA group (Table 1). There were also no
differences in pre-operative VAS scores for pain and
PONV.
Pre-medication with etoricoxib had a statistically
significant fentanyl-sparing effect 2–20 h post-
operatively (P ¼ 0.001). The fentanyl-sparing effects
were 43%, 57%, 44% and 23%, respectively, when the
E120 group was compared with the Pla group 2, 4, 10
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and 20 h post-operatively. Etoricoxib combined with
paracetamol reduced the fentanyl consumption by
23%, 53%, 48% and 21%, respectively, when compared
with the Pla group (Fig. 1). The addition of para-
cetamol to etoricoxib pre-medication did not improve
the analgesic effect of the pre-medication (Fig. 1).
With respect to post-operative pain intensity, there
were no statistically significant differences between
the groups in the repeated measures analysis, or
when analysing the time points separately and across
all groups.
There were no statistically significant differences
between the groups in the repeated measures analy-
sis of PONV or fatigue, although the Pla group
needed more fentanyl. The proportions of patients
whose highest PONV score at the ward was above
three were, however, 33% in the Pla group, 18% in the
E120 group and 5% in the Eþ P group. The difference
between the Pla and E þ P groups was significant
(P ¼ 0.033). However, there was no difference
between the groups with regard to the number of
doses of rescue anti-emetic.
There were no statistically significant differences
between the groups with regard to blood loss,
duration of anaesthesia or duration of surgery
(Table 2). All patients were satisfied or very satisfied
with their pain management (five-point scale) 20 h
post-operatively. There was, however, a significant
(P ¼ 0.041) difference in the proportion of very
satisfied patients between the groups, the propor-
tions being 50%, 73% and 86% in the Pla, E120 and
E þ P groups, respectively. The difference between
the Pla and E þ P groups was the only statistically
significant difference (P ¼ 0.018).
Discussion
We found that etoricoxib pre-medication reduced the
need for supplemental analgesics after laparoscopic
cholecystectomy. An opioid-sparing effect was seen
throughout the study when compared with placebo.
Combining paracetamol with etoricoxib in the pre-
medication did not result in a further reduced
fentanyl consumption. Our findings do not agree
with a recent study by Romundstad et al. (13), which
supports the practice of combining paracetamol with
an NSAID for the relief of acute pain. Hyllested et al.
(14) reviewed post-operative pain management
when using NSAIDs, paracetamol or a combination.
They also found very limited data concerning the
Table 1
Demographic data and ASA physical status in the different pre-medication groups [mean and standard deviation (SD) or percentage].
All differences between the groups were non-significant.
Pre-medication group*
E120 (n ¼ 24) E þ P (n ¼ 25) Pla (n ¼ 23)
Mean SD % Mean SD % Mean SD %
Age (years) 46.0 12.2 45.2 10.7 45.3 8.8
Sex
Male 21 20 30
Female 79 80 70
Weight (kg) 79 14 84 12 78 15
Height (cm) 169 8 170 8 170 9
ASA†
I 38 40 48
II 54 56 39
III 8 4 13
*E120, etoricoxib 120 mg; E þ P, etoricoxib 120 mg combined with 1 g of paracetamol; Pla, placebo.
†ASA, physical status score of the American Society of Anesthesiologists.
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Fig. 1. Mean cumulative number of fentanyl doses (50 mg) 1, 2, 4,
10 and 20 h post-operatively in the three pre-medication groups
(etoricoxib 120 mg, etoricoxib 120 mg combined with paracetamol
1 g, and placebo). The number of fentanyl doses normalized by
square-root transformation; the difference in these transformed
variables was examined by repeated measures analysis of variance
with the least significant difference multiple comparisons test.
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combination, but their results suggested some bene-
fit. The power of the present study, however, was
planned to reveal the fentanyl-sparing effect of
etoricoxib and a combination of etoricoxib with
paracetamol, not the difference between the two.
One small dose (1 g) of paracetamol was given
before the operation as pre-medication, and the
duration of paracetamol action was limited to the
first few hours after surgery. In addition, the fentanyl
doses used during the operation (total of 4 mg/kg)
and the local infiltration of bupivacaine in the
incisions have an important effect on the additional
pain treatment needed during the first few hours
post-operatively. However, we wanted to use maxi-
mal pain-relieving methods in order to represent the
usual Finnish peri-operative care. Infiltration with
bupivacaine and moderate doses of fentanyl during
cholecystectomy may have attenuated the possible
opioid-sparing effect of paracetamol.
No differences between the three groups were
encountered with respect to the duration of the
operation or to bleeding during the operation.
There is a causal relationship between the bleeding
time and the operation time. NSAIDs prolong the
bleeding time but, according to our results, pre-
medication with etoricoxib did not increase the
operation time.
In summary, pre-medication with etoricoxib had
a statistically significant fentanyl-sparing effect 2–20
h after laparoscopic cholecystectomy. Combining
paracetamol with etoricoxib in the pre-medication
did not have any additional fentanyl-sparing effect.
Pre-treatment with etoricoxib or combined etoricoxib
and paracetamol did not have an effect on the degree
of post-operative nausea and incidence of vomiting/
retching, although the Pla group needed more fen-
tanyl. Etoricoxib pre-medication did not alter the
operation time and/or blood loss during surgery. All
patients were satisfied or very satisfied with the pain
management 20 h post-operatively.
In conclusion, etoricoxib is suitable for pre-
medication before laparoscopic cholecystectomy as
it reduces the need for supplemental post-operative
opioids. Opioid-related side-effects, however, were
not reduced in the present study, despite the
observed opioid-sparing effect of etoricoxib
and combined etoricoxib and paracetamol. The
effectiveness of etoricoxib pre-medication should be
confirmed in other more painful procedures.
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Conventional nonsteroidal anti-inflammatory drugs (NSAIDs)
have a well-documented nephrotoxic action. Still, there are only
few studies that have investigated the nephrotoxicity of cyclo-
oxycenase-2-inhibitors during the perioperative period. Thirty
patients scheduled for elective laparoscopic hysterectomy were
enrolled in this prospective, randomized double-blind study.
Patients were randomized into two groups: a saline-treated
control group (placebo) and 80 mg parecoxib-treated group
(parecoxib). The samples for the analyses of serum and urine
were collected at the induction of anesthesia, two hours thereaf-
ter, two hours from the end of anesthesia, and on the first postop-
erative day (POD). S-crea, S-urea, S-cystatin C, S-Na, S-K,
U-1mikroglobulin/U-crea, U-GST/U-crea, and U-GST/U-crea
were analyzed from the samples. Urine output was measured
every hour for the first five hours, and total amount of urine was
measured until the first postoperative day. There were no clinical
and few statistical significant differences between the two groups
in the renal measurements during the study period. The urinary
output was also similar in the two groups. A single dose of 80 mg
of parecoxib was well tolerated by the kidneys in the short-term
perioperative use in patients undergoing laparoscopic hysterec-
tomy with ASA physiological status I-II and age under 60 years.
Keywords COX-2-inhibitor, parecoxib, laparoscopy surgery,
drug safety, kidney function, glutathione-S-
transferases
INTRODUCTION
The nephrotoxic effects of conventional nonsteroidal
anti-inflammatory drugs (NSAIDs) are well documented.
The adverse renal effects occur because of inhibition of
the synthesis of cyclooxygenase-derived prostaglandins.
Coxibs, selective COX-2-inhibitors, raised the hope that
this kind of drugs would reduce adverse effects on both the
gastrointestinal track and the kidneys. COX-2 is inducible
in most tissues in response to injury or inflammation, but
both COX-1 and COX-2 are constitutively expressed in
the kidneys. COX-2 has been detected both in the tubular
component, macula densa, and the renal vascular
component, podocytes and arteriolar smooth muscle cells.
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COX-2-synthesized prostaglandins play certain roles in the
kidneys, like regulating perfusion pressure, handling salt
and water intake, and renin release.[1–5] These roles
become more important in stressed states like hypov-
olemia, sepsis, and heart failure, when the glomerular
filtration rate is already compromised.[1–5]
Pneumoperitoneum for laparoscopy has been associated
with transient oliguria.[6] In spite of oliguria, renal tubular
ischaemia was not detected in laparoscopic operations
when measuring urinary N-acetyl-b-D-glucosaminidase.[7]
Possible causes of oliguria include diminished renal blood
flow secondary to renal vascular compression, direct renal
parenchymal compression, ureter obstruction, and
changed systemic hormonal levels.
There are only a few studies investigating the nephro-
toxicity of NSAID or coxibs during perioperative
period.[8–10] We decided to study the renal adverse effect
of a single dose of the COX-2 inhibitor, parecoxib 80mg,
in patients undergoing laparoscopic hysterectomy. We
assumed that the combination with laparoscopic surgery
might reveal renal adverse effects of parecoxib in the peri-
operative period when measuring sensitive markers of
both tubular and glomerular damage. Urinary glutathione-
S-transferases (GSTs) have been used to detect tubular
injury.[7,11] GSTs are cytosolic enzymes that have many
isomers. GST and GST are the main isomers in the kidney.
Elevated urinary GST- levels are correlated with the prox-
imal tubular injury and GST levels with distal tubular
injury.[12] Serum cystatin C is a cysteine protease inhibitor,
for which production is independent of age, sex, and
muscle mass.[13] It is freely filtered at the glomerulus,
which makes it an ideal marker of the glomerular filtration
rate (GFR).
The COX-2 inhibitors have lost their popularity
because of documented risk of cardiovascular events.[14]
However, their single, acute use at surgery can be safe,
especially when coxibs unlike conventional NSAIDs do
not enhance surgical bleeding.[15]
MATERIALS AND METHODS
The study was approved by the local ethic committee
and the Finnish National Agency for Medicines. Written
informed consent was obtained from each patient. Thirty
patients scheduled for elective laparoscopic hysterectomy
were enrolled in this prospective, randomized double-
blind study. The inclusion criteria were age between 30
and 60 years, ASA physiological status I-II, and weight
between 50 and 80 kg. The exclusion criteria were allergy
to aspirin-like drugs or sulphonamide, bronchial asthma,
liver or renal disturbances, peptic ulcer, bleeding disorder,
pregnancy, substance abuse, and chronic pain.
Patients were randomized into two groups: a saline-
treated control group (group placebo) and 80 mg pare-
coxib treated group (group parecoxib). The randomization
procedure involved computer-generated random numbers
in opaque envelopes. The study medication was given
intravenously before the induction of anesthesia in the
operation room. All solutions were colorless in a volume
of 4 ml and were prepared by a staff nurse otherwise not
involved in the study.
Anesthesia was standardized. Induction was with fenta-
nyl 2 g/kg, propofol 2–3 mg/kg, and rocuronium 0.6 mg/kg.
An equal amount of fentanyl was given about 3 minutes
before skin incision. Warm (37°C) CO2 insufflation was
used, and intra-abdominal pressure was kept at 12 mmHg.
A semi-closed breathing system with fresh gas flow of
2–3 l/min was used. Anesthesia was maintained with
sevoflurane in air/O2 66/34% and adjusted to keep systolic
blood pressure level between 85–130 mmHg (sevoflurane
end tidal concentration, about 2%). Muscle relaxation was
maintained between TOF 0/4 and 2/4 with rocuronium.
EtCO2 was maintained between 5.0 and 5.5% by adjusting
the ventilation. Residual neuromuscular block was antago-
nized with neostigmine and glycopyrrolate. Ringer’s
acetated solution, bolus 5 mL/kg continued by 5 mL/kg/h,
was administered during the operation. Five hundred ml of
4% gelatin solution was used if surgical blood loss was
over 400 ml. One liter of mixture 0.3% of NaCl in 5%
glucose was administered during the next 12 hours after
operation.
A urinary bladder catheter was inserted after induc-
tion of anesthesia to measure urine output and collect urine
samples. The samples for the analyses of serum and urine
were collected during the induction of anesthesia, two
hours thereafter, two hours after anesthesia, and on the
first postoperative day (POD). The samples of serum crea-
tinine, urea, sodium, potassium, a-1-microglobulin, and
cystatin C were analyzed on the consecutive working day.
Serum creatinine clearance was calculated by the Cockroft
and Gault formula.[16] Samples for GST were conserved in
a tube with stabilizer (containing mertiolate and azide) and
stored at −20°C before analysis. S-crea, S-urea, S-cysC,
S-Na, s-K, U-a-1-microglobulin/U-crea, U-aGST/U-crea,
and U-pGST/U-crea were analyzed according to good
laboratory practice (GLP) by the laboratory of Tampere
University Hospital. Abbreviations, method with analyzer,
and normal limits of the laboratory data are listed in the
Table 1. Urine output was measured hourly for the first
four hours, and total amount of urine output was measured
until the first post-operative day.
Post-operative pain was managed by patient-con-
trolled analgesia device (PCA), programmed to deliver
50 g of fentanyl during two minutes. The lockout time was
5 min, and the maximum dose was 500 g/h during the first
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two hours in the recovery room and 250 g/h on the ward
until 20 hours after the end of the surgery. During emer-
gence from anesthesia, the recovery room nurses were
allowed to give additional fentanyl boluses via the PCA
device on request of the patients. No other pain treatment
was allowed during the study period.
Normally distributed, continuous, demographic data
are expressed by means and standard deviations and tested
by t-test. Categorized variables (ASA status) are presented
as percent frequencies, with Pearson2-test as the signifi-
cance test. The laboratory data are treated as continuous.
Due to skewed distribution of S-crea, S-urea, S-cysC, S-
Na, S-K, U--1-micro/U-crea, U-GST/U-crea, and U-GST/
U-crea, the data are expressed by medians and interquar-
tile ranges and the difference between treatment groups is
tested by Mann-Whitney test. p < 0.05 was considered sta-
tistically significant. The analysis was accomplished with
SPSS for Windows, version 14.02.
RESULTS
There were no significant differences between the
treatment groups concerning age, BMI, ASA risk classifi-
cation, serum creatinine clearance, the duration of the sur-
gery or anesthesia, and total blood loss (see Table 2). The
baseline renal measurements did not differ between the
two groups (measurement 1 in Table 3). There were few
statistically but no clinically significant differences
between groups in any renal measurement during the study
period (measurements 2, 3, and 4 in Table 3). The values
of U-pGST/U-crea were increased two hours after the
Table 1 
Abbreviations, methods for analyses, and normal values of the laboratory data
Measured parameters Abbreviation Method and analyzer Normal values
Serum creatinine S-Crea Cobas Integra (Roche Diagnostic, 
Basel, Switzerland)
<95 μmol/L
Serum urea S-Urea Cobas Integra 2.6–6.4 mmol/L
Serum sodium S-Na Cobas Integra 137–145 mmol/L
Serum potassium S-K Cobas Integra 3.5–4.5 mmol/L
Serum cystatin C S-CysC Turbidimetric Dako (Dako 
Cytomation, Glostrup, Denmark)
< 1.4 mg/L under 
50 yr < 1.5 mg/L 
over 50 yr
Urinary a-1-mikroglobulin/
urinary creatinine
U-a-1-miglo/u-crea Behring Nephelometric Analyzer, 
Behring AG, Mahrburg, Germany/
Cobas Integra
0.04–0.7 mg/mmol
Urinary a-glutathione-
S-transferase/urinary 
creatinine
U-aGST/u-crea NEPHKIT (Biotrin International Ltd, 
Dublin, Ireland), measured with 
Multiscan EX analyzer (Labsystems, 
Helsinki, Finland)/ Cobas Integra
0.10–1.93 μg/mmol
Urinary p-glutathione-S-
transferase/ urinary creatinine
U- pGST/u-crea NEPHKIT (Biotrin International Ltd, 
Dublin, Ireland), measured with 
Multiscan EX analyzer (Labsystems, 
Helsinki, Finland)/ Cobas Integra
0.25–7.41 μg/mmol
Table 2 
Demographic factors
Placebo, 
n = 15
Parecoxib, 
n = 15
p
Age, mean 
(SD) year
50.5 (4.5) 48.5 (7.9) 0.389
BMI, mean 
(SD) kg/m2
25.2 (2.4) 24.8 (2.9) 0.725
Frequencies, n (%) 
of ASA 1
10 (67) 10 (67) 1.000
Duration of surgery, 
mean (SD) min
103 (34) 103 (28) 0.971
Duration of 
anesthesia, mean 
(SD) min
138 (36) 134 (38) 0.810
Total blood loss, 
med (min-max) ml
100 (50–200) 150 (50–400) 0.186
Creatinine clearance, 
mean (SD) mL/min
105.9 (23.3) 100.7 (20.4) 0.517
Differences were tested by t-test, Mann-Whitney test, or Pear-
son chi-squared test.
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beginning of anesthesia in both groups. The increase was
also statistically significant (Wilcoxon signed ranks test),
p = 0.013 in the parecoxib and p = 0.033 in the placebo
groups, when compared to baseline levels. The number of
patients is mentioned at each measurement because the
data was either missing or the outliers were omitted (seven
measurements). One-third of the measurements of urinary
a-1-microglobulin was undetectable (<5.2 mg/L), which
makes statistical analysis impossible. However, there
was no clinical difference between the groups in urinary
a-1-microglobulins. The urinary output during the first
four hours was small in volume, but there was no
difference between the groups (see Figure 1). On the first
postoperative day, the total amount of urine output was
recorded only in few patients.
DISCUSSION
The aim of our study was to reveal renal adverse
effects of the COX-2-inhibitor, parecoxib 80 mg, by
measuring the sensitive markers of both tubular and glom-
erular damage in patients undergoing laparoscopic hyster-
ectomy. However, we were not able to find any clinical
and few statistical significant differences between the
placebo and the parecoxib groups during the study period,
the first 20 perioperative hours.
Renal adverse events reported with COX-2-inhibitors
occur in less than 2% of the population,[5] which means
that a much larger sample size than ours would be needed
to find differences in such outcomes. Therefore, we
recruited patients with relatively increased risk for renal
Table 3 
Distributions of renal measurements
Measurement 1 Measurement 2 Measurement 3 Measurement 4
n Md [IQ] n Md [IQ] n Md [IQ] n Md [IQ]
S-Crea
Placebo 14 62 [54–66] 15 61 [49–64] 15 59 [52–64] 12 56 [47–60]
Parecoxib 14 61 [58–67] 14 60 [57–69] 14 63 [56–71] 13 57 [55–70]
p 0.662 0.370 0.347 0.127
S-Urea
Placebo 14 4.2 [3.6–5.4] 15 4.0 [3.5–5.0] 15 4.2 [3.5–5.0] 12 2.7 [2.3–3.1]
Parecoxib 15 3.7 [2.8–4.8] 15 3.3 [2.9–4.0] 15 3.3 [3.0–4.8] 13 2.4 [2.2–3.8]
p 0.101 0.124 0.229 0.978
S-CysC
Placebo 15 0.71 [0.64–0.84] 15 0.65 [0.56–0.78] 15 0.66 [0.56–0.72] 12 0.67 [0.55–0.78]
Parecoxib 15 0.74 [0.66–0.85] 15 0.67 [0.55–0.76] 15 0.66 [0.57–0.83] 13 0.68 [0.60–0.78]
p 0.534 0.967 0.663 0.624
S-Na
Placebo 14 139 [138.5–141] 15 140 [138–141] 14 139 [138–141] 11 137 [136–139]
Parecoxib 15 140 [139–142] 15 139 [138–141] 15 140 [137–141] 13 139 [136–142]
p 0.504 0.705 0.965 0.253
S-K
Placebo 14 4.2 [4.0–4.2] 15 4.2 [4.0–4.4] 14 4.0 [3.9–4.2] 12 3.6 [3.4–3.8]
Parecoxib 15 4.1 [4.0–4.3] 14 4.1 [4.0–4.4] 12 4.1 [4.0–4.6] 13 4.0 [3.8–4.2]
p 0.965 0.774 0.091 0.001
U-aGST/u-crea
Placebo 13 0.62 [0.17–1.75] 13 0.15 [0.02–0.93] 12 0.13 [0.04–0.98] 11 0.58 [0.15–0.99]
Parecoxib 14 2.07 [0.33–2.46] 13 0.42 [0.05–0.77] 13 0.15 [0.05–0.67] 10 0.50 [0.01–0.98]
p 0.133 0.554 0.723 0.597
U-pGST/u-crea
Placebo 13 4.5 [1.6–5.5] 13 17.3 [11.8–22.9] * 12 2.1 [0.7–3.6] 10 1.7 [0.9–4.0]
Parecoxib 14 2.8 [1.2–6.5] 13 12.2 [1.9–36.6] * 13 3.1 [0.3–7.1] 10 2.1 [0.6–3.7]
p 0.808 0.457 0.663 0.821
Differences between the groups were tested by Mann-Whitney test.
*p < 0.05 compared with measurement 1 levels.
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incidents. The risk factors were laparoscopic surgery,
anesthesia, moderate rather than abundant fluid adminis-
tration, and high dose of parecoxib. The dose of parecoxib
was 80mg intra venously, which is same as maximal daily
dose. The recommended dose of parecoxib for periopera-
tive use is 40 mg twice daily. Furthermore, sensitive mark-
ers of renal adverse effects were used.
Oliguria was detected in both groups and might be
explained by the laparoscopic surgery. The measured
increase in U-pGST/U-crea ratio two hours after the
beginning of anesthesia in both groups was statistically but
also clinically significant (see normal values, Table 1).
It can be explained by the operation itself and indicates
some distal tubular damage to occur. The values normal-
ized during the first 20 postoperative hours. Between the
groups there was no difference, although there was a
tendency of higher values in the control group. This under-
lines the safety of parecoxib, because COX-2 is expressed
in the distal tubular component, macula densa, which
damage can be detected by U-pGST.
In our study, the preoperative level of U-aGST/U-
crea was surprisingly high in both groups. In the parecoxib
group, it was even over normal values. One explanation is a
preoperative fasting, which causes a relative dehydration.
The values were lowest two hours after anesthesia, which
differs from the study showing an increase at that time
point when comparing ketorolac to normal saline in
patients undergoing breast surgery.[9] This emphasizes the
differences in the action sites of the kidneys between the
traditional NSAIDs and coxibs.
Cystatin C was employed as a sensitive marker of
GFR.[13,17,18] Because there was no increase in its levels,
we can assume that there was no clinically significant
decrease in GFR during the study period in either group.
The Cochrane meta-analysis of effects of nonsteroidal
anti-inflammatory drugs on postoperative renal function in
adults with normal renal function did not find any
clinically meaningful difference between NSAIDs and
placebo.[19] There is no such meta-analysis of coxibs
available. Koppert et al. were able to show a small pare-
coxib-associated decrease in creatinine clearance perioper-
atively in elderly patients whose creatinine varied between
44–144 mol/L.[10] There are also studies where short term
use of COX-2 inhibitors had no effect on glomerular filtra-
tion rate[20–22] or even protected the kidney from other
harmful effects.[21,22] There might also be heterogeneity in
COX-2 inhibitors because celecoxib seemed to be more
tolerated by the kidneys than rofecoxib in animal
model.[23] This emphasizes the importance of clinical stud-
ies.
The major limitations of this study are small sample
size and large variation of data. Both increase the risk of
type II error. We had assumed that our stressful study
setting would have increased sensitive renal markers’
values even in this small study population. The knowledge
of large data variation in a clinical setting provides valu-
able information for other researchers.
We conclude that a single dose of 80 mg parecoxib was
well tolerated by the kidneys during the next 20
perioperative hours in patients undergoing laparoscopic
hysterectomy with ASA physiological status I–II and age
under 60 years. It should not be withheld from such patients
because of concerns about postoperative renal impairment.
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ORIGINAL ARTICLEPersistent pain following knee arthroplasty
Pia A.E. Puolakka, Michael G.F. Rorarius, Miika Roviola, Timo J.S. Puolakka, Klaus Nordhausen and
Leena LindgrenBackground and objective The prevalence of persistent pain
after orthopaedic surgery has been the subject of only few
studies and the risk factors for persistent pain have been
evaluated even more rarely. The purpose of the present study
was to evaluate the degree and the risk factors of persistent pain
after knee arthroplasty.
Methods The prevalence of persistent postoperative pain after
knee replacement was evaluated with a questionnaire in a large,
register-based cross-sectional prevalence study. The main
hypothesis was that the type of operation (primary, bilateral,
revision) would influence the prevalence of persistent
postoperative pain. Logistic regression analysis was performed
to test the hypothesis and to find other possible risk factors for
the development of persistent pain.
Results The total number of patients was 855. The operation
was a primary arthroplasty in 648 patients (75.7%), a bilateral
arthroplasty in 137 patients (21.1%) and a revision arthroplastyright © European Society of Anaesthesiology. U
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of operation was not associated with the prevalence of
persistent pain, but the degree of early postoperative pain was
the strongest risk factor. If the degree of pain during the first
postoperative week was from moderate to intolerable, the risk
for the development of persistent pain was three to 10 times
higher compared with patients complaining of mild pain during
the same period. Other risk factors were the long duration of
preoperative pain and female sex.
Conclusion Intensity of early postoperative pain and delayed
surgery increase the risk of the persistent pain after knee
arthroplasty.
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Persistent postoperative pain, which is defined as pain
lasting for more than 3 months, is today a well known
problem independent of the type of surgery.1–3 The
highest prevalences are reported after leg amputation
(60–80%),4 thoracotomy and sternotomy (20–50%).5–9
Futhermore, routine operations such as mastectomy,10
hernioplasty,11–13 cholecystectomy14 and caesarean sec-
tion15 may also lead to persistent pain in approximately
12–30% patients.
The prevalence of persistent pain after orthopaedic
surgery has been the subject of only few studies16–24
and the risk factors for persistent pain have been eval-
uated even more rarely.17,18,21–23 The purpose of the
present study was to evaluate the degree and the risk
factors of persistent pain after knee arthroplasty with a
questionnaire in a large, register-based cross-sectional
prevalence study. Primary injury influences the intensity
of forthcoming pain.25,26 The main hypothesis, therefore,
was that the type of operation (primary, bilateral, revi-
sion) would influence the development of persistent
postoperative pain.
Patients and methods
Patients who had undergone knee arthroplasty during the
period from 1st September 2002 to 28th February 2004arthroplasty specialized hospital. The study was
approved by the Ethic Committee of the hospital. Writ-
ten informed consent was obtained from each patient.
The total number of patients was 855. The operation was
a primary arthroplasty in 648 patients (75.7%), a bilateral
arthroplasty in 137 patients (21.1%) and a revision arthro-
plasty in 70 patients (8.2%). If a patient was operated
several times, the last operation was taken into account.
The preoperative pain intensity was evaluated by a
surgeon and taken from the hospital registry (none, mild,
moderate, severe). All patients were operated on spinal
anaesthesia and an epidural catheter was inserted for
postoperative pain relief. Epidural analgesia was discon-
tinued on the first postoperative day to ensure early
rehabilitation. The early complications such as deep
infection and/or dislocation of prosthesis during first 2
months were taken from the hospital registry.
A questionnaire and a consent form with a prestamped
return envelope were mailed to all patients in July 2004.
In the case of no reply, a reminder was sent once. The
time interval between the performed operation and the
questionnaire was minimum 4 months and maximum 22
months. The demographics were asked. All the other
questions considered preoperative and postoperative
pain. The duration of preoperative pain and the intensity
of postoperative pain during the first week (mild, mod-
erate, severe, unbearable) were asked. If the patient still
was suffering any pain in operated knee while receiving
the questionnaire, the pain intensity during rest and
exercise was evaluated. The degree of disturbance of
daily life and sleep due to pain (none, mild, moderate,nauthorized reproduction of this article is prohibited.
DOI:10.1097/EJA.0b013e328335b31c
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Fig. 2
Disturbance of daily life (a) and sleep (b) because of persistent pain in
primary, bilateral and revision arthroplasty groups. P-values are 0.52 (a)
and 0.70 (b), respectively.severe) and the consumption of analgesics for persistent
pain at the operated knee were asked.
The data from the returned questionnaires and from the
hospital registry were analysed using multiple logistic
regression analysis. The dependent variable was the pain
at the time of the questionnaire. The explanatory vari-
ables were treatment, age (centred at the age of 70 years
and including a quadratic term), sex, BMI, pain score and
duration prior to surgery, pain score during the first week
after operation, type of prosthesis and diagnosis. The
numeric variables are reported by means with standard
deviations (SD) and the categorical variables are pre-
sented as absolute and relative frequencies. The results
of the univariate and multivariate logistic regressions are
presented as odds ratios (ORs) with 95% confidence
intervals (CI). P-values are also given for univariate
analysis. Logistic regression was used instead of linear
regression because the object of the study-persistent pain
or not was binominal.
All computations have been made by using R.27
Results
The response rate of the questionnaire was 65.7% in total;
66.8% in the primary arthroplasty group, 69.3% in the
bilateral arthroplasty group and 48.6% in the revision
arthroplasty group. Pain was not experienced only during
exercise (Fig. 1a) but also during rest (Fig. 1b). Thirty-fiveight © European Society of Anaesthesiology. Una
Fig. 1
Persistent pain during exercise (a) and rest (b) in primary, bilateral and
revision arthroplasty groups. P-value is 0.32 (a, b).
European Journal of Anaesthesiology 2010, Vol 27 No 00percent of patients suffered from daily life disturbing pain
(35.6% in primary, 31.6% in bilateral and 38.2% in revision
arthroplasty groups, respectively) a minimum of 4 months
after the operation (Fig. 2a). Twenty-five percent of
patients had disturbances of sleep due to pain (Fig. 2b).
The intensity of pain was mostly mild or moderate. The
proportion of patients who still used analgesics because of
pain in the operated knee was 45.5% after primary arthro-
plasty, 43.2% after bilateral arthroplasty and 41.2% after
revision arthroplasty (P¼ 0.86).
The variables listed in Table 1 were all assumed to be
risk factors for persistent pain. The results of univariate
logistic regressions are presented in Table 2. Backward
selection in the multivariate logistic regression left only
age and its quadratic term, sex, the duration of pain prior
to surgery and early postoperative pain in the final model.
Age was entered in the model also quadratically and a
possible interaction between age and treatment was
considered. According to the primary hypothesis, the
operation itself, primary, bilateral or revision arthroplasty
and the type of prosthesis, demi-arthroplasty or total
arthroplasty, were still left to the final model. The surgi-
cal complications checked from the registry were so few
that they were left out from the regression analysis.
Following Harrell,28 Somer’s Dxy rank correlation of
the final model was 0.50, which corresponds to a value
of the area under the Receiver Operating Characteristicuthorized reproduction of this article is prohibited.
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Table 1 Variables evaluated for persistent pain
Primary N¼433 Bilateral N¼95 Revision N¼34
Age (years; meanSD) 69.2 (8.9) 65.1 (8.9) 71.2 (10.3)
BMI (kg/m2; meanSD) 29.5 (4.7) 29.6 (4.5) 28.1 (4.0)
Sex F/M (N) 304/129 64/31 28/6
Diagnosis OA/RA (N) 412/12 93/2 30/4
Presurgical pain score N (%); no pain/mild pain 29 (7.0) 4 (4.0) 7 (21.0)
Moderate, occasional pain 219 (51.0) 39 (41.0) 13 (38.0)
Moderate, continuous pain 149 (35.0) 42 (45.0) 9 (26.0)
Severe pain 30 (7.0) 9 (10.0) 5 (15.0)
Presurgical duration of pain N¼419 N¼94 N¼30
12 months N (%) 43 (10.0) 3 (3.0) 5 (17.0)
>12 months N (%) 377 (90.0) 91 (97.0) 25 (83.0)
Early postsurgical pain N¼417 N¼93 N¼34
Mild N (%) 111 (27.0) 26 (28.0) 14 (41.0)
Moderate N (%) 194 (45.0) 36 (39.0) 14 (41.0)
Severe N (%) 104 (24.0) 26 (28.0) 5 (15.0)
Unbearable N (%) 18 (4.0) 5 (5.0) 1 (3.0)
F, female; M, male; OA, osteoarthritis; RA, rheumatoid arthritis.(ROC) curve of 0.75. The indices of unreliability and
discrimination were U¼0.0039 and D¼ 0.1443.
The results of the multivariate logistic regression (OR
with 95% CI) are shown in Table 3. ORs for continuous
variables refer to one unit changes.
Discussion
The aim of the present study was to find out whether the
magnitude of the primary injury, the type of surgery,
influences the development of persistent postoperative
pain. Logistic regression analysis was chosen to test our
hypothesis and to find any other risk factors for the
development of persistent pain. Persistent pain after
knee arthroplasty was relatively common (35.0%), but
the type of surgery did not correlate with pain. Instead,
female sex, long duration of pain prior to surgery and high
intensity of pain during the first postoperative week led to
persistent pain.right © European Society of Anaesthesiology. U
Table 2 Results of univariate logistic regression analysis
Variable Persistent pain Yes/No (N)
Treatment; primary 101/304
Treatment; bilateral 22/70
Treatment; revision 7/22
Age 130/396
BMI 127/388
Sex: Male 25/128
Sex: Female 105/268
Diagnosis; RA 6/18
Diagnosis; OA 124/378
Presurgical duration of pain; 12 months 5/42
Presurgical duration of pain; >12 months 122/342
Presurgical pain score; no pain or mild 7/31
Moderate, occasional 59/196
Moderate, continuous 48/139
Severe 15/24
Early postsurgical pain score; mild 11/128
Moderate 50/179
Severe 56/74
Unbearable 13/11
CI, confidence interval; OA, osteoarthitis; OR, odds ratio; RA, rheumatoid arthritis.Pain is themain indication for knee arthroplasty and pain
relief is the most important postoperative outcome.
However, there are only few studies concerning persist-
ent pain as an outcome measure after knee arthro-
plasty,16–18,20–22,24 although most studies focus on the
survival of prosthesis.
The prevalence of persistent pain in the present study
was significantly higher than in the majority of the earlier
studies. The study of Brander et al.17 reported 22.6%
prevalence of significant pain [Visual Analog Scale (VAS)
>4] at 3 months, 18.4% at 6 months and 13.1% at 1 year.
In another study the prevalence of moderate pain was
10%, but their time point was at 7 years.20 Lundblad
et al.23 reported prevalences that are more in line with our
study. The prevalence of persistent pain was 24% at rest
and 66% with movement at 18 months after operation.23
The differences between the studies may be explained
by studymethods. Pain was not assessed by clinician suchnauthorized reproduction of this article is prohibited.
OR 95% CI P
0.9460 0.5473–1.5844 0.8370
0.9577 0.3695–2.2048 0.9230
0.9792 0.9580–1.0007 0.0577
1.0126 0.9686–1.0580 0.5779
2.0060 1.2530–3.3124 0.0049
0.9841 0.4026–2.7638 0.9736
2.9965 1.2677–8.8217 0.0236
1.3331 0.5876–3.4339 0.5173
1.5293 0.6639–3.9819 0.3459
2.7679 1.0021–8.2608 0.0558
3.2504 1.6861–6.8002 0.0008
8.8059 4.4952–18.6975 <0.0001
13.7521 5.0873–39.0962 <0.0001
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Table 3 Results of multivariate logistic regression analysis
Variable OR 95% CI
Bilateral versus primary arthroplasty 0.8864 0.4802–1.5875
Revision versus primary arthroplasty 1.0904 0.3650–2.8885
Duration of presurgical pain >12 months 2.8431 1.1448–8.6517
Age, centred at 70 years 1.0141 0.9855–1.0434
Age, squared and centred at 70 years 1.0027 1.0007–1.0048
Sex, female 1.9084 1.1434–3.2787
Moderate postsurgical pain versus mild 3.1135 1.5857–6.6186
Severe postsurgical pain versus mild 8.1686 4.0428–17.8303
Unbearable postsurgical pain versus mild 10.6857 3.6304–32.6282
CI, confidence interval; OR, odds ratio.as in some earlier studies.17,20 The patients were able to
express their feelings confidentially by the questionnaire
used, which might have increased the prevalence of pain.
Pain was not graded by VAS17,23 but by verbal terms.
Mostly patients suffered from mild to moderate pain.
The percentile from severe and unbearable pain (up to
21.4%) was more consistent with the study by Brander
et al.17
Our strongest risk factor for persistent pain was the
intensity of early (the first week) postoperative pain.
Earlier studies with knee replacement have not included
the intensity of early postoperative pain to their risk
analysis, which has left the intensity of preoperative pain
as a risk factor.17,23 Instead, the study with total hip
arthroplasty revealed that persistent postoperative pain
was related to the recalled intensity of early postoperative
pain rather than the intensity of preoperative pain.22
Women had an increased risk for persistent pain, which is
related to many biological and psychosocial factors as
discussed previously elsewhere.29,30
Advanced age seems to reduce the risk of persistent pain
after general surgery.31–33 In our study, age was not a
linear risk factor for persistent pain, which is in line with
other orthopaedic studies.17,23
Other factors associated with increased postoperative
pain are anxiety and undiagnosed depression,17 but our
questionnaire was not designed to diagnose depression
or anxiety.
The hypothesis of this studywas that the larger the tissue
injury (bilateral versus unilateral arthroplasty group), the
higher the prevalence of persistent pain. Surprisingly
there was no association in this respect. These results are
in line with a previous study34 and support the consensus
to offer bilateral knee arthroplasty when needed.
The retrospective nature of data, the response rate
(65.7%) and the variable time period from surgery to
the questionnaire were the major limitations in the
present study. To minimize the effect of retrospectivity,
the original size of the study was designed to be large
enough to draw conclusions. The response rate can be
considered sufficient, but a higher response rate may
have been obtained with several reminders. This in turnight © European Society of Anaesthesiology. Una
European Journal of Anaesthesiology 2010, Vol 27 No 00would have increased the power of the results. Especially
the patients after revision knee arthroplasty were less
likely to answer than others and the response rate 48.6%
among them could not be regarded high enough. Any-
way, the original size of study sample was 855 patients,
which is enormous compared with previous prevalence
studies.17,20,23
The time interval from surgery to the questionnaire
varied from 4 to 22months. Thus, definition for persistent
postoperative pain is filled.3 However, the long time
interval for some responders may have affected the
memory for preoperative pain. This problem was
addressed by gaining the scores for preoperative pain
scores from the hospital registry. Moreover, a long inter-
val usually increases the possibility of false negatives,35
which in turn underlies the significance of postoperative
pain score as a risk factor for persistent postoperative
pain. Altogether a fixed time interval between surgery
and the questionnaire would have increased the quality of
this study.
Although we found that the intensity of postoperative
pain was a strong risk factor for persistent pain, a pro-
spective study with observed pain intensities and the
amounts of used analgesics should be carried out to
confirm this finding.
Persistent pain after knee arthroplasty seems to be a far
more frequent problem than assumed. The preoperative
duration of pain and the intensity of early postoperative
pain are the risk factors that we are able to influence by
our own practice.3 Surgery should be planned before the
patients develop long lasting pain conditions and pain
management during postoperative period and early reha-
bilitation should be considered as a challenge for the
entire team. Prioritization according these findings is
suggested in the healthcare system.
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Appendix
Background:
1. Weight ________kg
2. Height ________cm
Pre/Post-surgical status
3. How long did you suffer from pain at the operated knee before surgery?________months
4. How much did this pain disturb your daily life?
1 not at all
2 little
3 to some extent
4 a lot
5. How long did you have pain after surgery? _______weeks/months
6. How would you describe the pain during the first week after the operation?
1 mild
2 moderate
3 severe
4 unbearable
At present
7. Do you still have pain at your operated knee?
1 yes, move to the question 9
2 no (no futher questions)
8. Do you have pain at rest?
1 yes
2 no
9. How would you describe the degree ofpain at rest?
1 mild
2 moderate
3 severe
4 unbearable
10. Do you have pain at exercise?
1 yes
2 no, move to the question 12
11. How would you describe the degree of pain at exercise?
1 mild
2 moderate
3 severe
4 unbearable
12. How much does this pain disturb your daily life?
1 not at all
2 little
3 to some extent
4 a lot
13. How much does this pain disturb your sleep?
1 not at all
2 little
3 to some extent
4 a lot
14. Do you still use any medicine against post-surgical knee pain? Which?______
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